EP2694110B1 - Novel polysaccharide derivatives and dosage forms - Google Patents
Novel polysaccharide derivatives and dosage forms Download PDFInfo
- Publication number
- EP2694110B1 EP2694110B1 EP12714149.7A EP12714149A EP2694110B1 EP 2694110 B1 EP2694110 B1 EP 2694110B1 EP 12714149 A EP12714149 A EP 12714149A EP 2694110 B1 EP2694110 B1 EP 2694110B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- particles
- polysaccharide derivative
- polysaccharide
- dosage form
- micrometers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001282 polysaccharide Polymers 0.000 title claims description 117
- 239000005017 polysaccharide Substances 0.000 title claims description 117
- 239000002552 dosage form Substances 0.000 title claims description 62
- 150000004676 glycans Chemical class 0.000 title claims 27
- 239000002245 particle Substances 0.000 claims description 153
- 229920003086 cellulose ether Polymers 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 39
- 239000010419 fine particle Substances 0.000 claims description 33
- 239000004480 active ingredient Substances 0.000 claims description 31
- 229920002678 cellulose Polymers 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 238000009826 distribution Methods 0.000 claims description 21
- 238000013268 sustained release Methods 0.000 claims description 19
- 239000012730 sustained-release form Substances 0.000 claims description 19
- 239000002671 adjuvant Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 150000004804 polysaccharides Chemical class 0.000 description 86
- -1 polysaccharide ethers Chemical class 0.000 description 43
- 238000000227 grinding Methods 0.000 description 26
- 239000001913 cellulose Substances 0.000 description 21
- 235000010980 cellulose Nutrition 0.000 description 21
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 21
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 21
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 19
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 239000000546 pharmaceutical excipient Substances 0.000 description 13
- 239000012798 spherical particle Substances 0.000 description 13
- 239000008187 granular material Substances 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 10
- 238000007907 direct compression Methods 0.000 description 10
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 238000010191 image analysis Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229920000609 methyl cellulose Polymers 0.000 description 8
- 235000010981 methylcellulose Nutrition 0.000 description 8
- 229960001300 metoprolol tartrate Drugs 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 7
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 7
- 229960000991 ketoprofen Drugs 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 6
- 229920013820 alkyl cellulose Polymers 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- RFRMMZAKBNXNHE-UHFFFAOYSA-N 6-[4,6-dihydroxy-5-(2-hydroxyethoxy)-2-(hydroxymethyl)oxan-3-yl]oxy-2-(hydroxymethyl)-5-(2-hydroxypropoxy)oxane-3,4-diol Chemical compound CC(O)COC1C(O)C(O)C(CO)OC1OC1C(O)C(OCCO)C(O)OC1CO RFRMMZAKBNXNHE-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920000896 Ethulose Polymers 0.000 description 3
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005056 compaction Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000003703 image analysis method Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 229920003096 Methocel™ K100M Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
- 229940029985 mineral supplement Drugs 0.000 description 2
- 235000020786 mineral supplement Nutrition 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010001981 Amoebic infections Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920003095 Methocel™ K15M Polymers 0.000 description 1
- 229920003094 Methocel™ K4M Polymers 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229920003089 ethylhydroxy ethyl cellulose Polymers 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Definitions
- This invention relates to novel polysaccharide derivatives and dosage forms produced from one or more polysaccharide derivatives, one or more active ingredients, and one or more optional adjuvants.
- Sustained release dosage forms have found wide usage in a variety of technology areas, such as in personal care or agricultural applications, water treatment and particularly in pharmaceutical applications. Sustained release dosage forms are designed to release a finite quantity of a compound into an aqueous environment over an extended period of time. Known sustained release pharmaceutical dosage forms contain a medicament or a vitamin whose rate of release is controlled by a polymeric matrix. Sustained release pharmaceutical dosage forms are desirable because they provide a method of delivering a long-lasting dose in a single application without overdosing.
- U.S. Patent No. 4,734,285 discloses that the release of an active composition from a solid tablet can be prolonged by employing a fine particle sized hydroxypropyl methylcellulose ether composition as an excipient in the solid tablet.
- the particle size of the hydroxypropyl methylcellulose ether is so small that at least 90 percent by weight of the cellulose ether particles pass through a 100 mesh screen (149 micrometers mesh size), and preferably at least 97 percent by weight of the cellulose ether particles pass through a 140 mesh screen (105 micrometers mesh size) to achieve a long release profile. While such hydroxypropyl methylcellulose ether particles provide excellent release profiles to tablets, these particles of very small size are known to have poor flow properties. A poor flowability of the cellulose ether particles can lead to problems in the manufacturing of dosage forms such as tablets. Problems can include increased variability in tablet weight or tablet crushing strength from tablet-to-tablet as well as variation in the amount of active ingredient incorporated into each dosage form. Poor particle flow can also lead to consolidation of the powder bed in processing equipment, such as storage bins and tablet press feed hoppers.
- WO 2008/127794 addresses the poor flowability of the hydroxypropyl methylcellulose ether disclosed in U.S. Patent No. 4,734,285 .
- WO 2008/127794 discloses a granular material having a mean particle diameter of 150 to 800 micrometers and an untapped bulk density of 0.1 to 0.35 g/cm 3 , the main component of the granular material being a cellulose derivative.
- the granular material is a useful excipient for sustained-release dosage forms, particularly for excipients to be used in a direct compression process, due to the good flow and the good compactibility of the granular material leading to strong, hard tablets, with small variability in tablet-to-tablet physical properties, in combination with reproducible kinetics of the sustained release of the active ingredient.
- the low density of the granular material may cause some problems when blending the granular material with the active ingredient. Due to the low density of the granular material, the weight of the blend of granular material and active material in the blender typically has to be reduced to avoid overfilling of the blender, which reduces the throughput through the blender. Also, formulators may need to pre-compress the blend of granular material and active ingredient to be able to fill tablet dies with the target tablet weight.
- one object of the present invention is to find polysaccharide derivatives which are useful as an excipient in dosage forms, particularly as excipients in sustained release dosage forms, and which have an improved flowability, as compared to the cellulose ethers disclosed in U.S. Patent No. 4,734,285 .
- Another object of the present invention is to find polysaccharide derivatives which are useful as an excipient in dosage forms, particularly as excipients in sustained release dosage forms, and which have an improved flowability and/or an increased bulk density, as compared to the cellulose ethers disclosed in WO 2008/127794 .
- One aspect of the present invention is a polysaccharide derivative having a median Equivalent Projected Circle Diameter (EQPC) of less than 140 micrometers and a particle size and shape distribution meeting condition A or B or both:
- EQPC median Equivalent Projected Circle Diameter
- Another aspect of the present invention is a dosage form which has been produced from a) one or more of the above-mentioned polysaccharide derivatives, one or more active ingredients, and one or more optional adjuvants.
- Yet another aspect of the present invention is a process for preparing a dosage form which comprises the step of I.) blending one or more of the above-mentioned polysaccharide derivatives, one or more active ingredients, and one or more optional adjuvants, and II.) compressing the blend to a dosage form.
- Yet another aspect of the present invention is the use of an above-mentioned polysaccharide derivative for producing a dosage form.
- the polysaccharide derivatives of the present invention have a median Equivalent Projected Circle Diameter (EQPC) of less than 140 micrometers.
- EQPC of a particle is defined as the diameter of a circle that has the same area as the projection area of the particle.
- the EQPC of particles can be determined using a high speed image analysis method which combines particle size and shape analysis of sample images. Such method is described in more details further below and in the prior art cited further below.
- a high speed image analysis system is commercially available from Sympatec GmbH, Clausthal-Zellerfeld, Germany as dynamic image analysis (DIA) system QICPICTM.
- DIA dynamic image analysis
- the median EQPC is the volume distribution average of all particles in a given sample of a particulate polysaccharide derivative.
- the median EQPC means that 50% of the EQPC of the particle distribution is smaller than the given value in ⁇ m and 50% is larger.
- Polysaccharide derivatives which are useful in the present invention have a median EQPC of less than 140 micrometers, preferably of no more than 130 micrometers, more preferably of no more than 125 micrometers and most preferably of no more than 120 micrometers.
- Polysaccharide derivatives which are useful in the dosage form of the present invention generally have a median EQPC of at least 30 micrometers, preferably at least 35 micrometers, more preferably at least 40 micrometers, and most preferably at least 45 micrometers.
- WO 2008/127794 discloses a granular material having a mean particle diameter of at least 150 micrometers, using a RapidVue 5X image analyzer which is commercially available from Beckman Coulter, Inc., California. USA; this corresponds to a median EQPC of at least 141 micrometers, measured using the dynamic image analysis (DIA) system QICPICTM.
- DIA dynamic image analysis
- polysaccharide derivatives in particulate form
- a polysaccharide derivative in particulate form, particularly a cellulose derivative generally contains particles of regular and irregular shapes. It has been surprisingly found that the flowability of a polysaccharide derivative can be controlled, influenced, and/or varied by classifying the particles of the polysaccharide derivative into fine particles of a certain maximum length as described further below, fibrous particles of a certain shape as described further below, and other particles and by controlling, influencing and/or varying the relative volume proportions of the fine particles, fibrous particles and other particles.
- the "other particles”, i.e., the particles which do not meet the definition of "fine particles” and “fibrous particles” are designated as "spherical particles". It has also been found that the relative volume proportion of the fine particles, fibrous particles and other particles does not only have an impact on the flow-ability of the polysaccharide derivative, but generally also on the bulk density of the polysaccharide derivative. When the polysaccharide derivative is used for producing dosage forms, such as tablets, it has even more surprisingly been found that the relative volume proportions of the fine particles, fibrous particles and other particles has an impact on the tablet to tablet variability of tablet weight and tablet hardness. A low tablet to tablet variability of tablet weight and tablet hardness is highly desirable.
- the volume proportions of the fine particles, fibrous particles and other particles of the polysaccharide derivative can be determined by a high speed image analysis method which combines particle size and shape analysis of sample images.
- An image analysis method for complex powders is described in: W. Witt, U. Köhler, J. List, Current Limits of Particle Size and Shape Analysis with High Speed Image Analysis, PARTEC 2007 .
- a high speed image analysis system is commercially available from Sympatec GmbH, Clausthal-Zellerfeld, Germany as dynamic image analysis (DIA) system QICPICTM.
- DIA dynamic image analysis
- the high speed image analysis system is useful for measuring the following dimensional parameters of particles:
- the volume of each particle type (fine particles, spherical particles and fibrous particles) in the powder sample is calculated from the medians of the number distribution of the respective LEFI and DIFI for fibrous particles, and the respective EQPC for fine particles and spherical particles. Number distributions are calculated from the DIFI, EQPC and LEFI for each particle within the sample.
- fine particles have a particle length LEFI of less than 40 micrometers and generally a particle length LEFI of at least 10 micrometers.
- the detection limit of the QICPICTM with a M7 optical system is 10 micrometers.
- fibrous particles For the purpose of the present invention a distinction between fibrous particles and other (spherical) particles is made if the particles have a particle length LEFI of more than or equal to 40 micrometers. This distinction is made based on the parameters from the image analysis that describes the shape of the particles; these parameters are elongation, sphericity and aspect ratio as defined above.
- Fibrous particles are typically particles characterized by irregular shape and length typically much larger than the diameter. Fibers can be straight or curved, thin or thick. Consequently, both shape and size information from the QICPICTM is used to define the fibrous particles.
- particles are "fibrous" particles if they meet one of the following definitions I or II: I) particles with an elongation equal or less than 0.35, an aspect ratio of equal or less than 0.45, and a LEFI of equal or greater than 40 micrometers; or II) particles with an elongation equal or less than 0.35, an aspect ratio of greater than 0.45, a sphericity of less than 0.7 and a LEFI of equal or greater than 40 micrometers.
- particles meet the definition of "spherical particles” if they have an elongation equal or less than 0.35, and an aspect ratio greater than 0.45, and a sphericity equal or greater than 0.70, and a LEFI equal or greater than 40 micrometers.
- particles also meet the definition of "spherical particles” if they have an elongation greater than 0.35 and a LEFI equal or greater than 40 micrometers.
- the volume of the spherical particles can be calculated by subtracting the volume of the fine particles and the volume of the fibrous particles from the total volume of the sample.
- volume fractions can be readily calculated from the volumes V, Vs and Vf as defined above. Since the densities of an individual fine particle, of an individual fibrous particle and of an individual spherical particle are all essentially the same, the volume fractions essentially correspond to the weight fractions.
- polysaccharide derivatives of the present invention have a volume fraction of fine particles of no more than 40%, preferably no more than 35%, more preferably no more than 30% and most preferably no more than 28%.
- Polysaccharide derivatives of the present invention generally have a volume fraction of fine particles of at least 2%.
- polysaccharide derivatives of the present invention have a volume fraction of fibrous particles of no more than 40%, preferably no more than 30% and more preferably no more than 20%.
- the polysaccharide derivatives of the present invention have a volume fraction of fibrous particles of one percent or more.
- the volume fraction of fibrous particles in the polysaccharide derivatives of the present invention is smaller than the volume fraction of fibrous particles in known polysaccharide derivatives. Moreover, the sum of the fine particles and of the fibrous particles in the polysaccharide derivatives of the present invention is not more than 50 volume percent, preferably not more than 45 volume percent, more preferably not more than 40 volume percent, most preferably not more than 35 volume percent, and particularly not more than 30 volume percent.
- polysaccharide derivatives of the present invention have a volume fraction of non-fine and non-fibrous other (i.e., spherical) particles of at least 50%, preferably at least 55%, more preferably at least 60%, most preferably at least 65%, and particularly at least 70%.
- Bulk density as used herein is defined as the ratio of apparent mass to volume of a material taken, called untapped bulk density. A useful procedure for measuring the untapped bulk density is described in the example section.
- Polysaccharide derivatives which are useful in the present invention generally have an untapped bulk density of more than 150 kg/m 3 , preferably more than 300 kg/m 3 , more preferably more than 350 kg/m 3 , and most preferably 400 kg/m 3 or more.
- the polysaccharide derivatives of the present invention have a flowability of at least 45 g/sec, preferably at least 50 g/sec, and more preferably at least 60 g/sec. Their flowability generally is up to 90 g/sec, but in ideal cases the flowability can be up to 100 g/sec or even up to 120 g/sec.
- the flowability as used herein is defined as the amount of the polysaccharide derivative particles that flows out of a flow test apparatus having a vertically arranged column of about 300 mm with a diameter of about 90 mm and a conic shaped bottom geometry having a height of about 110 mm, a vertex angle of about 40° and an outlet diameter of about 50 mm.
- the flow test apparatus is described in more detail in the examples and is illustrated in Fig. 1 .
- the polysaccharide derivatives of the invention have particle flow that exceeds polysaccharide derivatives known in the art with an equivalent bulk density.
- the polysaccharide derivatives of the present invention preferably have a median LEFI of from 60 to 350 micrometers, more preferably from 63 to 300 micrometers, most preferably from 65 to 270 micrometers.
- the median LEFI means that 50% of the LEFI of the particle distribution is smaller than the given value in ⁇ m and 50% is larger, as calculated from the volume distribution.
- Preferred polysaccharide derivatives are polysaccharide ethers and polysaccharide esters, more preferably cellulose derivatives, such as cellulose ethers and esters, most preferably water-soluble cellulose ethers. They can have one or more substituents, preferably of the types: hydroxyethyl, hydroxypropyl, hydroxybutyl, methyl, ethyl, propyl, dihydroxypropyl, carboxymethyl, sulfoethyl, hydrophobic long-chain branched and unbranched alkyl groups, hydrophobic long-chain branched and unbranched alkyl aryl groups or aryl alkyl groups, cationic groups, acetate, propionate, butyrate, lactate, nitrate or sulfate, of which some groups, such as, for example, hydroxyethyl, hydroxypropyl, hydroxybutyl, dihydroxypropyl and lactate, are capable of forming grafts.
- the substituents of the polysaccharides according to the invention are not limited to these groups.
- Typical polysaccharide derivatives are guar derivatives, starch derivatives, chitin or chitosan derivatives, and preferably cellulose derivatives, but the polysaccharide derivatives according to the invention are not limited to these.
- cellulose derivatives are hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), ethyl hydroxyethyl cellulose (EHEC), carboxymethyl cellulose, carboxymethyl hydroxyethyl cellulose (CMHEC), hydroxypropyl hydroxyethyl cellulose (HPHEC), methylcellulose (MC), methyl hydroxypropyl cellulose (MHPC), methyl hydroxyethyl cellulose (MHEC), carboxymethyl cellulose (CMC), hydrophobically modified hydroxyethyl cellulose (hmHEC), hydrophobically modified hydroxypropyl cellulose (hmHPC), hydrophobically modified ethyl hydroxyethyl cellulose (hmEHEC), hydrophobically modified carboxymethyl hydroxyethyl cellulose (hmCMHEC), hydrophobically modified hydroxypropyl hydroxyethyl cellulose (hmHPHEC), hydrophobically modified methylcellulose (hmMC), hydrophob
- Preferred cellulose derivatives are cellulose esters or cellulose ethers.
- Preferred cellulose ethers are carboxy-C 1 -C 3 -alkyl celluloses, such as carboxymethyl celluloses; carboxy-C 1 -C 3 -alkyl hydroxy-C 1 -C 3 -alkyl celluloses, such as carboxymethyl hydroxyethyl celluloses; C 1 -C 3 -alkyl celluloses, such as methylcelluloses; C 1 -C 3 -alkyl hydroxy-C 1-3 -alkyl celluloses, such as hydroxyethyl methylcelluloses, hydroxypropyl methylcelluloses or ethyl hydroxyethyl celluloses; hydroxy-C 1-3 -alkyl celluloses, such as hydroxyethyl celluloses or hydroxypropyl celluloses; mixed hydroxy-C 1 -C 3 -alkyl celluloses, such as hydroxyethyl hydroxyprop
- Particularly preferred cellulose derivatives are methylcellulose, methyl hydroxyethyl cellulose, methyl hydroxypropyl cellulose, hydroxypropyl cellulose and carboxymethyl cellulose, particularly in its sodium form.
- Two or more types of polysaccharide derivatives preferably cellulose derivatives, more preferably two or more types of cellulose ethers, can be incorporated in combination in the dosage form of the present invention.
- a combination of two different types of hydroxypropyl methylcelluloses or methylcelluloses or a combination of i) a hydroxypropyl methylcellulose or methylcellulose and ii) a carboxymethyl cellulose can be used in combination for preparing the dosage forms of the present invention.
- the water-soluble cellulose ether is a methylcellulose with a methyl degree of substitution DS methyl of from 1.2 to 2.2, preferably from 1.5 to 2.0; or a hydroxypropyl methylcellulose with a DS methyl of from 0.9 to 2.2, preferably from 1.1 to 2.0, and an MS hydroxypropyl of from 0.02 to 2.0, preferably from 0.1 to 1.2; or a hydroxyethyl methylcellulose with a DS methyl of from 1.15 to 2.3, preferably from 1.15 to 2.2, and an MS hydroxyethyl of from 0.03 to 1.0, preferably from 0.05 to 0.9; or a hydroxyethyl cellulose with an MS hydroxyethyl of from 1.2 to 3.0, preferably from 1.45 to 2.2.
- the determination of the ether side groups i.e. the DS methyl , MS hydroxyethyl and MS hydroxypropyl can be effected as described by K.L. Ketterer, W.E. Kester, D.L. Wiederrich, and J.A. Grover, Determination of Alkoxyl Substitution in Cellulose Ethers by Zeisel-Gas Chromatographie, Analytical Chemistry, Vol. 51, No. 13, Nov 1979, 2172-76 .
- the viscosities of the water-soluble cellulose ethers can vary over a broad range.
- the viscosity of the cellulose ether is more than 150 mPa ⁇ s, preferably from 500 to 200,000 mPa ⁇ s, more preferably from 500 to 100,000 mPa ⁇ s, most preferably from 1000 to 80,000, particularly from 1000 to 60,000, determined in a 1.5 % by weight aqueous solution at 20 °C in a Haake RS600 rheometer with a cone and plate Geometry (CP-60/2°) at 20 °C and at a shear rate of 2.55 s - 1.
- the viscosity of the cellulose ether is from 1.2 to 200 mPa ⁇ s, preferably from 2 to 100 mPa ⁇ s, more preferably from 2.5 to 50 mPa ⁇ s, in particular from 3 to 30 mPa ⁇ s, measured as a 2 weight-% aqueous solution at 20 °C according to ASTM D2363 - 79 (Reapproved 2006).
- Such low viscosity cellulose ethers can be produced in a known manner by partial degradation of higher viscosity cellulose ethers.
- polysaccharide derivatives preferably polysaccharide ethers and polysaccharide esters
- the production process involves activating the polysaccharide, such as cellulose, for example by treatment with an alkali metal hydroxide, reacting the thus treated polysaccharide with a derivatizing agent, such as an etherifying or esterifying agent, and washing the polysaccharide derivative to remove byproducts.
- a derivatizing agent such as an etherifying or esterifying agent
- the polysaccharide derivative generally has a moisture content of from 30 to 60 percent, typically from 45 to 55 percent, based on the total weight of the moist polysaccharide derivative.
- washing liquors While the preferred washing liquor may depend on the specific type of polysaccharide derivative, preferred washing liquors generally are water, isopropanol, acetone, methylethylketone or brine. More preferred washing liquors generally are water or brine.
- Cellulose derivatives are generally washed at a temperature of from 20 to 120 °C, preferably from 65 to 95 °C.
- a solvent-moist, preferably a water-moist filter cake is obtained after washing and separating the polysaccharide derivative from the washing liquor.
- the moist polysaccharide derivative is usually obtained in the shape of moist granules, moist lumps and/or a moist paste.
- the moist polysaccharide derivative can be directly subjected to a drying-grinding step as described below or, e.g., for logistics reasons, can be subjected to an intermediate drying step.
- Drying-grinding is generally described in the art as drying and grinding simultaneously in one process step with one unit operation, typically an impact mill or an air swept impact mill. Drying is typically accomplished with a combination of hot gas and mechanical energy. Hot air is most commonly used but also hot nitrogen gas can be used. The hot gas and the wet product stream are generally fed via separate inlets into the mill, typically hot gas from the bottom and wet product at a side entrance via a feed screw system connected to the mill.
- Superheated vapor of a solvent such as superheated steam, or a steam/inert gas mixture or a steam/air mixture can also be used as heat-transfer gas and transport gas, as described in more detail in European Patent Applications EP 0 954 536 A1 (equivalent to US Patent No.
- the moist polysaccharide derivative is subjected to drying-grinding in a gas-swept impact mill, preferably an air-swept impact mill, wherein the polysaccharide derivative is subjected to an impacting and/or shearing stress.
- gas-swept impact mills are Ultra Rotor mills (Altenburger Maschinen Jaeckering, Germany) or Turbofiner PLM mills (PALLMANN Maschinenfabrik GmbH & Co. KG, Germany).
- Gas classifier mills are also useful gas-swept impact mills, for example, the Hosokawa Alpine Air Classifier mill - ZPS Circoplex Hosokawa Micron Ltd., Cheshire, England.
- the median particle diameter and the bulk density of the polysaccharide derivative can be controlled by controlling the temperature of the polysaccharide derivative prior to drying-grinding, as described in patent application PCT/US10/043522, filed 28 July 2010 .
- the temperature of the polysaccharide derivative prior to drying-grinding is preferably controlled and optionally varied or adjusted in a range from 5 to 70 °C, more preferably from 6 to 65 °C, most preferably from 6 to 60 °C.
- the temperature of the polysaccharide derivative prior to drying-grinding is preferably controlled and optionally varied or adjusted by controlling and optionally varying or adjusting the temperature of the added liquid and/or the jacket temperature of the compounder. This can also be achieved without interrupting the drying-grinding process.
- the moisture content of the polysaccharide derivative prior to drying-grinding is preferably 40 percent or more, more preferably 45 percent or more, and most preferably 50 percent or more prior to drying-grinding, based on the total weight of the moist polysaccharide derivative.
- the moisture content is preferably 90 percent or less, more preferably 85 percent or less, and most preferably 82 percent or less prior to drying-grinding, based on the total weight of the moist polysaccharide derivative.
- the moisture content can be determined by ASTM method D-2363-79 (reapproved 1989).
- the median diameter, the median length and the bulk density of the particles after drying-grinding can be controlled and optionally varied or adjusted by controlling and optionally varying or adjusting the circumferential speed of the drying-grinding device, in addition to controlling the temperature of the polysaccharide derivative prior to drying-grinding.
- the circumferential speed of the drying-grinding device is preferably controlled and optionally varied or adjusted in a range from 55 to 140 m/s, more preferably from 70 to 120 m/s, most preferably from 90 to 115 m/s.
- the polysaccharide derivative is useful as an excipient for a dosage form, particularly as an excipient for a sustained-release dosage form, which means that it has the function to regulate the release of an active ingredient from the dosage form over an extended period of time.
- sustained-release is used herein synonymously to the terms prolonged release; extended release; sustained release; depot release; time release; controlled release; modified release or prolonged action.
- sustained release is an approach by which active compounds, such as biologically active compounds, are made available at a rate and duration designed to accomplish an intended effect.
- an oral controlled release drug delivery system is a device or dosage form that regulates the release of a drug into the gastrointestinal tract, thereby controlling the absorption rate of that drug in order to achieve a desired blood plasma profile.
- These dosage forms are designed to provide a constant or nearly constant drug level in plasma with reduced fluctuation via a slow, continuous release of drug over an extended period of time.
- the sustained-release dosage form of the present invention it generally takes between 0.75 and 36 hours, more preferably between 4 and 30 hours, and most preferably between 8 and 24 hours to release the active ingredient from the dosage form in its entirety.
- polysaccharide derivatives are useful as an excipient for dosage forms, particularly for sustained-release dosage forms in a variety of technological fields, for example in personal care, laundry care or agricultural applications, water treatment, and particularly in human or animal health care applications, most specifically pharmaceutical applications wherein a biologically active ingredient is selected from vitamins, herbal and mineral supplements and drug substances.
- the above-described polysaccharide derivatives have a unique combination of features which makes them very useful as an excipient in dosage forms, for example in pharmaceutical dosage forms.
- the polysaccharide derivatives have good flow properties. They can be efficiently blended with a biologically active ingredient, and, if desired, with one or more optional adjuvants, even in the absence of a substantial amount of added solvent or heat. It is to be understood that one or more types of the above-described polysaccharide derivatives and one or more types of active ingredients can be blended with one or more optional adjuvants to prepare a dosage form. Preferably the blending process is conducted at about room temperature.
- Active ingredients are known in the art and include, among others, detergents or surfactants for laundry care applications; fertilizers, herbicides or pesticides in formulations designed to release the bioactive agents over a prolonged period of time in agricultural applications.
- a wide range of biologically active ingredients are useful, such as vitamins, herbals and mineral supplements and drugs.
- the biologically active ingredient includes hydrophobic, hydrophilic and amphiphilic compounds.
- the biologically active ingredient may be used for treating indications such as, by way of example and without limitation, inflammation, gout, hypercholesterolemia, microbial infection, AIDS, tuberculosis, fungal infection, amoebic infection, parasitic infection, cancer, organ rejection, diabetes, heart failure, arthritis, asthma, pain, congestion, urinary tract infections, vaginal infection, seizure-related disorders, depression, psychosis, convulsion, diabetes, blood coagulation, hypertension and birth control.
- the amount of the biologically active ingredient loaded into a pharmaceutical dosage form will vary according to the pharmacological activity of the compound, the indication being treated, the targeted dosing regimen, the projected method of administration, the integrity or stability of the final composition or other such reasons.
- the amount of the active ingredient generally is at least 0.5 percent, preferably at least 1 percent, more preferably at least 5 percent, most preferably at least 10 percent, based on the total weight of the dosage form, and generally up to 75 percent, preferably up to 65 percent, more preferably up to 55 percent, most preferably up to 45 percent, based on the total weight of the dosage form.
- the active ingredient is generally solid and preferably has a median particle diameter as defined further above of from 1 to 500 micrometers.
- Useful optional adjuvants are known in the art and are generally solid, such as one or more fillers, pigments, colorants, flavorants, disintegrating agents, binders, plasticizers, salts, acidic and basic pH modifiers, antioxidants and/or lubricants.
- adjuvants examples include acacia, corn starch, guar gum, potato starch, alginic acid, stearic acid, magnesium stearate, lactose, sucrose, dicalcium phosphate, microcrystalline cellulose, sugars, minerals, cellulose powder or cellulose fibers.
- Optional adjuvants are generally solid and preferably have a median particle diameter as defined further above of from 1 to 500 micrometers.
- the blend of one or more types of polysaccharide derivatives, one or more active ingredients and one or more optional adjuvants has good flow properties and exhibits a minimum of segregation which means that the blend shows excellent uniformity. By this it is meant that if the blend is divided into portions, the content of the active ingredient is essentially the same in all portions.
- the blend can be directly filled into capsules or can be subjected to a direct compression process to produce tablets or similar dosage forms. The efficient feeding of the blend to a capsule filling device or to a compression device allows for uniform weights of the dosage forms.
- the combination of good powder flow and high bulk density, generally minimum segregation and good compactibility allows the blend to be efficiently processed to a dosage form in a direct compression process, even in the absence of a substantial amount of added solvent, heat, pressure or additional processing steps.
- solvent or heat is not added in a sufficient amount to the blend of the active ingredient and the polysaccharide derivative to effect granulation of the blend.
- the direct compression process is conducted in the absence of any amount of added solvent or heat.
- Direct compression processes to produce tablets are known in the art. Typically a compaction pressure of from 150 MPa to 375 MPa, preferably from 200 to 300 MPa is sufficient to produce tablets of good quality.
- the direct compression process of the present invention eliminates the need for formulators of dosage forms to subject the blend of one or more polysaccharide derivatives, one or more active ingredients and one or more optional adjuvants to a wet granulation step before compressing the blend to a tablet.
- a wet granulation step involves wetting, drying and screening steps, which is not desirable for moisture-sensitive or heat-sensitive drugs.
- the direct compression process of the present invention also eliminates the need for a complicated dry-granulation process. In addition, products made by the direct compression process are less costly than those produced when wet or dry granulation processes are employed.
- sustained release pharmaceutical dosage forms with excellent drug release profiles can be produced when using the polysaccharide derivatives of the present invention, which have a better flowability than the cellulose ethers recommended for sustained release pharmaceutical dosage forms in U.S. Patent No. 4,734,285 and which have an improved flowability and/or an increased bulk density, as compared to the cellulose ethers disclosed in WO 2008/127794 .
- the polysaccharide derivatives of the present invention can form at least a portion of a coating, particularly a compression coating, of a dosage form to control the release of the active ingredient.
- a coating particularly a compression coating
- the granular material forms at least a portion of the matrix of a dosage form.
- Viscosities of the cellulose ethers are measured as a 2 weight percent aqueous solution using a Brookfield LVT viscosimeter at 20 °C.
- CRT20000PA Sodium carboxymethyl cellulose powder having a degree of DS(carboxymethyl) of 0.65 - 0.95 and a viscosity of about 20000 mPa ⁇ s.
- the sodium carboxymethyl cellulose powder is commercially available from Dow Wolff Cellulosics (a subsidiary of The Dow Chemical Company) as WalocelTM C CRT20000PA.
- a commercially available continuous compounder with heating and cooling jacket is used to add water to dry cellulose ether.
- the compounder jacket is supplied with a fluid of -10 °C to 70 °C.
- Cellulose ether at a moisture level of less than 5 % is fed continuously at a feed rate of 10-30 kg/h into the compounder.
- Water of a temperature of 5 °C to 20 °C is continuously added at rates of 1-120 kg/h to the compounder resulting in a moisture level of about 50-82 %.
- the more specific reaction conditions are listed in Table 1 below.
- the wet product is transported continuously via a transport belt into a mill feed unit (Altenburger Maschinen Jaeckering GmbH, Hamm, Germany).
- the bottom blades of the vessel agitator press the paste into a single augur screw mounted at the bottom of the vessel.
- the wet product is forced through a perforated plate directly into the side of an Ultrarotor II "S" impact mill (Altenburger Maschinen Jaeckering GmbH, Hamm, Germany) between the first and second grinding stage.
- the mill is equipped with seven grinding stages.
- the bottom three grinding stages are equipped with standard grinding bars.
- Turbo-bars are installed in the top four grinding stages.
- a co-rotating finger sifter wheel with twelve blades is installed on the top of the 7th grinding stage.
- the interior of mill jacket has the standard Altenburger corrugated stationary grinding plates.
- the rotor of the impact mill is operated at a circumferential speed of 91 or 114 m/s.
- a hot nitrogen stream is fed at a rate listed in Table 1 below into the bottom of the mill.
- a cyclone is used to separate the dried product from the nitrogen.
- the final product moisture is smaller than 3 % by weight.
- Hydroxypropyl methylcellulose ether having a degree of substitution of methoxyl groups of 22.6% and of hydroxypropoxyl groups of 10.3 %, and a viscosity of 114,700 Pa.s, is used as a comparative material. It is representative of state of the art controlled release grade cellulose ether and referred to as CR cellulose ether. The production of controlled release grade cellulose ethers is disclosed in U.S. Patent No. 4,734,285 .
- Hydroxypropl methylcellulose ether having a degree of substitution of methoxyl groups of 22.7% and of hydroxypropoxyl groups of 10.0% , and a viscosity of 103,300mPa.s, is used as a comparative material.
- the hydroxypropyl methylcellulose of Comparative Example B can be produced by a granulation process as described in WO 2008/127794.
- the hydroxypropyl methylcellulose of Comparative Example B is referred to as "Direct Compression" (DC) cellulose ether.
- Table 1 Comparative
- the DIFI, Equivalent Projected Circle Diameter (EQPC), length (LEFI), elongation, aspect ratio and sphericity of the particles in the powder samples of Examples 1-17 and Comparative Examples A and B are measured or calculated with a high speed image analyzer (high speed image analyzer sensor QICPIC, Sympatec, Germany, with dry disperser RODOS/L with an inner diameter of 4 mm and dry feeder VIBRI/L and divide Software WINDOX5, Vers. 5.3.0 and M7 lens).
- the volume percentages of fine particles, fibrous particles, and other (spherical) particles are calculated from these parameters as described further above and listed in Table 2 below.
- the median EQPC (50% of the EQPC of the particle distribution is smaller than the given value in ⁇ m and 50% is larger, as calculated from the volume distribution) and the median LEFI (50% of the LEFI of the particle distribution is smaller than the given value in ⁇ m and 50% is larger, as calculated from the volume distribution) are also listed in Table 2 below.
- the apparatus for the flow test method consists of two Plexiglass pieces, specifically a cylindrical part (column) which is 305 mm tall with an inner diameter of 89 mm; and a conical part (a vertex down cone) with a height of 108 mm, a top diameter of 89 mm and an outlet diameter (orifice) of 51 mm.
- the vertex angle ⁇ of the cone is 39.2 °. By all diameters the inner diameters are meant, excluding the wall thickness.
- a schematic illustration of the apparatus for the flow test method is illustrated in Figure 1 .
- the vertex angle ⁇ of the right circular vertically inverted cone i.e.
- vertex down cone is the angle made by a cross section through the vertex and the center of the base.
- the total volume of the tester is 2.32 liters. The two pieces are connected.
- the tester is set up vertically with the vertex of the cone at the bottom.
- the particle flow rate is measured by first blocking the outlet of the cone with a plate, and then filling the tester completely with non-compacted polysaccharide derivative in particulate form by pouring the polysaccharide derivative into the top of the cylinder and filling the cylinder completely.
- the polysaccharide derivative is discharged from the hopper into a collection container by removing the plate.
- a timer is used to record the total time for the particles to discharge from the hopper.
- the polysaccharide derivative in the collection container is then weighed and the time and weight are recorded.
- the flowability also designated as flow rate, is calculated as the ratio of the weight of polysaccharide derivative per unit time. Each material is tested four times and the average flow rate is recorded.
- the untapped bulk density of the polysaccharide derivative in particulate form is measured using a Hosokawa Powder Characteristics Tester: Model PT-N available from Hosokawa Micron, Osaka Japan.
- Table 2 (Comparative) Example Median LEFI [microns] Median EQPC [microns] Bulk Density [kg/m 3 ] Flowability [g/s] Fine particles [% volume] Fibrous particles [% volume] Other (spherical) particles [% volume] 1 77.8 58.86 337 106 12.8 1.9 85.3 2 123.34 72.13 312 56 7.4 8.4 84.2 3 93.88 65.11 399 66 9.1 3.8 87.1 4 103.25 68.1 330 72 7.6 4.9 87.5 5 66.0 48.2 375 76.8 28.1 2.3 69.6 6 84.23 62.94 351 77 7.3 2.4 90.4 7 178.34 95.07 399 84 3.4 13.5 83.2 8
- Table 2 illustrates the improved flowability, and in the preferred embodiments of the present invention also the higher bulk density, of the polysaccharide derivatives of the present invention, as compared to the known polysaccharide derivatives of comparative Examples A and B.
- Ketoprofen compositions comprising the hydroxypropyl methylcellulose of Examples 13, 14, 15, 16, or 17 or Comparative Example A or B
- Ketoprofen dosage form The controlled drug release performance using a Ketoprofen dosage form is determined after 3 and 12 hours. Ketoprofen, hydroxypropyl methylcellulose, and impalpable lactose as listed in Table 3 are blended in a Turbula jar blender for 10 minutes. Magnesium stearate is added and the pharmaceutical composition blended for an additional 1 minute. The resulting formulated system is fed into a Manesty BETA tablet press with a target tablet weight of 400mg. The tooling used in the press is 10.3 mm in diameter round, flat-faced and bevel-edged.
- the tablet press is set at a speed of 12-14 RPM (revolutions per minute) and the tablets are compressed at a target compression force of 5000 lbs (22.2 kN), producing a compaction pressure of 266 MPa.
- Table 3 Ingredients Manufacturer Wt % hydroxypropyl methylcellulose The Dow Chemical Company, USA 30 Ketoprofen Spectrum Chemicals, USA 20 Impalpable Lactose Sheffield, USA 49 Magnesium Stearate Mallinckrodt, USA 1
- Tablets are allowed to relax for 24 hours before testing. Each tablet is weighted using an analytical balance and then each tablet is crushed using a HT-300 Hardness tester. The sustained release performance of the tablets is also compared. The release of ketoprofen is measured using 6 tablets from each formulation. Drug release is measured using a commercially available Varian Total Solution with Dual VK 7025 dissolution system. A USP Type II dissolution apparatus is used to determine drug release performance. The paddle stirring rate is set to 50 RPM and the dissolution media, maintained at 37°C, is 0.05M phosphate buffer at a pH of 5.8. Detection of dissolved ketoprofen is achieved using ultraviolet absorption spectrometry at a wavelength of 260nm.
- the drug release profiles of ketoprofen from tablets produced from compositions comprising the novel cellulose ethers of Examples 13, 14, 15, 16, and 17 as excipients show similar drug release as tablets produced from compositions comprising the CR grade or DC grade cellulose ethers of Comparative Examples A and B.
- Metoprolol tartrate compositions comprising the hydroxypropyl methylcellulose of Examples 13, 14 or 15 or Comparative Examples A or B
- Metoprolol tartrate, microcrystalline cellulose and Starch 1500® are blended as listed in Table 4 below in a V-blender for 10 minutes to prepare a pharmaceutical formulation. Magnesium stearate is added and the pharmaceutical composition is blended for an additional 1 minute.
- Table 4 Ingredients Manufacturer Wt % hydroxypropyl methylcellulose The Dow Chemical Company, USA 30 Metoprolol Tartrate (active ingredient) Mulji Mehta & Sons, Private Ltd, India 10 Avicel Microcrystalline Cellulose (PH 102) FMC Biopolymers, USA 49.5 Starch 1500® Colorcon, USA 10 Magnesium Stearate Mallinckrodt, USA 0.5
- the metoprolol tartrate compositions are compressed into tablets according to a direct compression process.
- the tablets are made using a Manesty BETA tablet press with a target tablet weight of 400mg.
- the tooling used in the press is 10.3 mm in diameter round, flat-faced and bevel-edged.
- the tablet press is set at a speed of about 17 RPM (revolutions per minute) and the tablets are compressed at a target compression force of 5000 lbs (22.2 kN), producing a compaction pressure of 266 MPa.
- the formulations are tableted with each run lasting about 45 minutes. Tablets are allowed to relax for 24 hours before testing. Each tablet is weighted using an analytical balance and then each tablet is crushed using a HT-300 Hardness tester.
- Table 5 below illustrates the comparison of properties of tablets produced from compositions comprising cellulose ethers listed in Table 5 below.
- Metoprolol tartrate formulations made using cellulose ethers of the present invention achieve the target tablet weight and show less tablet to tablet weight variability than those made from the formulations made using CR or DC grade cellulose ethers of Comparative Examples A or B. Achieving the target tablet weight and less tablet to tablet variability is an indication of the superior bulk density and flow properties of the cellulose ethers of the present invention.
- tablets produced from formulations comprising cellulose ethers of the present invention also have a significantly higher average tablet weight when compared to tablets produced from formulations comprising cellulose ethers of Comparative Example B.
- Table 5 also shows a comparison of tablet average hardness values for the metoprolol tartrate formulations. Tablets produced from formulations comprising cellulose ethers of the present invention show less variability in tablet to tablet hardness than tablets produced from formulations comprising known cellulose ethers of Comparative Example A.
- the sustained release performance of the tablets are also compared.
- the release of metoprolol tartrate is measured using 6 tablets from each formulation.
- the tablets are dissolved in deionized water at 37°C, USP II Apparatus at 50 rpm, using a commercially available Varian Total Solution with Dual VK 7025 dissolution system.
- the drug release profiles of metoprolol tartrate from tablets produced from compositions comprising the novel cellulose ethers of Examples 13, 14 or 15 as excipients show similar drug release as tablets produced from compositions comprising the known cellulose ethers of Comparative Example A or B.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
- This invention relates to novel polysaccharide derivatives and dosage forms produced from one or more polysaccharide derivatives, one or more active ingredients, and one or more optional adjuvants.
- Sustained release dosage forms have found wide usage in a variety of technology areas, such as in personal care or agricultural applications, water treatment and particularly in pharmaceutical applications. Sustained release dosage forms are designed to release a finite quantity of a compound into an aqueous environment over an extended period of time. Known sustained release pharmaceutical dosage forms contain a medicament or a vitamin whose rate of release is controlled by a polymeric matrix. Sustained release pharmaceutical dosage forms are desirable because they provide a method of delivering a long-lasting dose in a single application without overdosing.
U.S. Patent No. 4,734,285 discloses that the release of an active composition from a solid tablet can be prolonged by employing a fine particle sized hydroxypropyl methylcellulose ether composition as an excipient in the solid tablet. The particle size of the hydroxypropyl methylcellulose ether is so small that at least 90 percent by weight of the cellulose ether particles pass through a 100 mesh screen (149 micrometers mesh size), and preferably at least 97 percent by weight of the cellulose ether particles pass through a 140 mesh screen (105 micrometers mesh size) to achieve a long release profile. While such hydroxypropyl methylcellulose ether particles provide excellent release profiles to tablets, these particles of very small size are known to have poor flow properties. A poor flowability of the cellulose ether particles can lead to problems in the manufacturing of dosage forms such as tablets. Problems can include increased variability in tablet weight or tablet crushing strength from tablet-to-tablet as well as variation in the amount of active ingredient incorporated into each dosage form. Poor particle flow can also lead to consolidation of the powder bed in processing equipment, such as storage bins and tablet press feed hoppers. - The International Patent Application Publication No.
WO 2008/127794 addresses the poor flowability of the hydroxypropyl methylcellulose ether disclosed inU.S. Patent No. 4,734,285 .WO 2008/127794 discloses a granular material having a mean particle diameter of 150 to 800 micrometers and an untapped bulk density of 0.1 to 0.35 g/cm3, the main component of the granular material being a cellulose derivative. The granular material is a useful excipient for sustained-release dosage forms, particularly for excipients to be used in a direct compression process, due to the good flow and the good compactibility of the granular material leading to strong, hard tablets, with small variability in tablet-to-tablet physical properties, in combination with reproducible kinetics of the sustained release of the active ingredient. Unfortunately, it has been found that the low density of the granular material may cause some problems when blending the granular material with the active ingredient. Due to the low density of the granular material, the weight of the blend of granular material and active material in the blender typically has to be reduced to avoid overfilling of the blender, which reduces the throughput through the blender. Also, formulators may need to pre-compress the blend of granular material and active ingredient to be able to fill tablet dies with the target tablet weight. - Accordingly, one object of the present invention is to find polysaccharide derivatives which are useful as an excipient in dosage forms, particularly as excipients in sustained release dosage forms, and which have an improved flowability, as compared to the cellulose ethers disclosed in
U.S. Patent No. 4,734,285 . Another object of the present invention is to find polysaccharide derivatives which are useful as an excipient in dosage forms, particularly as excipients in sustained release dosage forms, and which have an improved flowability and/or an increased bulk density, as compared to the cellulose ethers disclosed inWO 2008/127794 . - One aspect of the present invention is a polysaccharide derivative having a median Equivalent Projected Circle Diameter (EQPC) of less than 140 micrometers and a particle size and shape distribution meeting condition A or B or both:
- A. non-compacted polysaccharide derivative particles have a flowability of at least 45 g/sec through a vertically inverted cone having a vertex angle of about 40° and an outlet diameter of about 50 mm, or
- B. i) no more than 40 volume percent of the polysaccharide derivative particles are fine particles having a particle length, LEFI, of less than 40 micrometers and ii) no more than 40 volume percent of the polysaccharide derivative particles are fibrous particles, and the sum of the fine particles and the fibrous particles does not exceed 50 volume percent.
- Another aspect of the present invention is a dosage form which has been produced from a) one or more of the above-mentioned polysaccharide derivatives, one or more active ingredients, and one or more optional adjuvants.
- Yet another aspect of the present invention is a process for preparing a dosage form which comprises the step of I.) blending one or more of the above-mentioned polysaccharide derivatives, one or more active ingredients, and one or more optional adjuvants, and II.) compressing the blend to a dosage form.
- Yet another aspect of the present invention is the use of an above-mentioned polysaccharide derivative for producing a dosage form.
-
-
Fig. 1 represents a schematic illustration of an apparatus for testing the flowability of a polysaccharide derivative in particulate form. -
Fig.2 illustrates the controlled release of a first drug from pharmaceutical dosage forms of the present invention and pharmaceutical dosages forms known fromU.S. Patent No. 4,734,285 andWO/2008/127794 . -
Fig. 3 illustrates the controlled release of a second drug from pharmaceutical dosage forms of the present invention and pharmaceutical dosages forms known fromU.S. Patent No. 4,734,285 andWO/2008/127794 . - The polysaccharide derivatives of the present invention have a median Equivalent Projected Circle Diameter (EQPC) of less than 140 micrometers. EQPC of a particle is defined as the diameter of a circle that has the same area as the projection area of the particle. The EQPC of particles can be determined using a high speed image analysis method which combines particle size and shape analysis of sample images. Such method is described in more details further below and in the prior art cited further below. A high speed image analysis system is commercially available from Sympatec GmbH, Clausthal-Zellerfeld, Germany as dynamic image analysis (DIA) system QICPIC™. For the purpose of the present invention the median EQPC is the volume distribution average of all particles in a given sample of a particulate polysaccharide derivative. The median EQPC means that 50% of the EQPC of the particle distribution is smaller than the given value in µm and 50% is larger. Polysaccharide derivatives which are useful in the present invention have a median EQPC of less than 140 micrometers, preferably of no more than 130 micrometers, more preferably of no more than 125 micrometers and most preferably of no more than 120 micrometers. Polysaccharide derivatives which are useful in the dosage form of the present invention generally have a median EQPC of at least 30 micrometers, preferably at least 35 micrometers, more preferably at least 40 micrometers, and most preferably at least 45 micrometers.
WO 2008/127794 discloses a granular material having a mean particle diameter of at least 150 micrometers, using a RapidVue 5X image analyzer which is commercially available from Beckman Coulter, Inc., California. USA; this corresponds to a median EQPC of at least 141 micrometers, measured using the dynamic image analysis (DIA) system QICPIC™. - It has been surprisingly found that the flowability of polysaccharide derivatives, particularly cellulose derivatives, in particulate form does not only depend on the median EQPC but also on the percentage of fine particles and fibrous particles. A polysaccharide derivative in particulate form, particularly a cellulose derivative, generally contains particles of regular and irregular shapes. It has been surprisingly found that the flowability of a polysaccharide derivative can be controlled, influenced, and/or varied by classifying the particles of the polysaccharide derivative into fine particles of a certain maximum length as described further below, fibrous particles of a certain shape as described further below, and other particles and by controlling, influencing and/or varying the relative volume proportions of the fine particles, fibrous particles and other particles. For the purpose of the present invention, the "other particles", i.e., the particles which do not meet the definition of "fine particles" and "fibrous particles" are designated as "spherical particles". It has also been found that the relative volume proportion of the fine particles, fibrous particles and other particles does not only have an impact on the flow-ability of the polysaccharide derivative, but generally also on the bulk density of the polysaccharide derivative. When the polysaccharide derivative is used for producing dosage forms, such as tablets, it has even more surprisingly been found that the relative volume proportions of the fine particles, fibrous particles and other particles has an impact on the tablet to tablet variability of tablet weight and tablet hardness. A low tablet to tablet variability of tablet weight and tablet hardness is highly desirable.
- The volume proportions of the fine particles, fibrous particles and other particles of the polysaccharide derivative can be determined by a high speed image analysis method which combines particle size and shape analysis of sample images. An image analysis method for complex powders is described in: W. Witt, U. Köhler, J. List, Current Limits of Particle Size and Shape Analysis with High Speed Image Analysis, PARTEC 2007. A high speed image analysis system is commercially available from Sympatec GmbH, Clausthal-Zellerfeld, Germany as dynamic image analysis (DIA) system QICPIC™. The high speed image analysis system is useful for measuring the following dimensional parameters of particles:
- LEFI: The particle length LEFI is defined as the longest direct path that connects the ends of the particle within the contour of the particle. "Direct" means without loops or branches.
- DIFI: The projection area of the particle divided by the sum of all lengths of the branches of the particle.
- Elongation: The particle elongation is the ratio of the diameter DIFI and the length LEFI of a particle, as defined by the formula DIFI / LEFI.
- EQPC: EQPC of a particle is defined as the diameter of a circle that has the same area as the projection area of the particle.
- Feret Diameter: Feret Diameter is also known as the caliper diameter. The distance between two tangents on opposite sides of a particle profile, that are parallel to some fixed direction, is the Feret Diameter. If a particle has an irregular shape, the Feret diameter usually varies much more than with regularly shaped particles.
- Minimal Feret Diameter (Fmin): The minimum distance between pairs of tangents to the particle projection in some fixed direction. The minimal Feret diameter is the smallest diameter after consideration of all possible orientations (from 0° to 180°). For irregularly shaped particle, Fmin can be significantly smaller than EQPC.
- Maximal Feret Diameter (Fmax): The maximum distance between pairs of tangents to the particle projection in some fixed direction. The maximal Feret diameter is the largest diameter after consideration of all possible orientations (from 0°to 180°). Fmax can be significantly larger than EQPC.
- Aspect ratio: The aspect ratio of a particle in the powder is the ratio of minimal to the maximal Feret diameter, Fmin/Fmax, and is another measure for the particle shape. Fmin/Fmax is between 0 and 1 for any particle.
- Sphericity: The ratio of the perimeter of a circle that has the same area as the projection area of the particle, PEQPC, to the perimeter of the real particle. Since the equivalent circle gives the smallest possible perimeter at a given projection area, the value of sphericity is between 0 and 1 for any particle. The smaller the value, the more irregular the shape of the particle.
- Use of a Dynamic Image Analysis DIA system QICPIC™ equipped with a RODOS dry powder disperser from Sympatec GmbH, Clausthal-Zellerfeld, Germany for a variety of powders is described in: W. Yu, K. Muteki, L. Zhang, and G. Kim, Prediction of Bulk Powder Flow Performance Using Comprehensive Particle Size and Particle Shape Distributions, JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 100, NO. 1, JANUARY 2011.
- The volume of each particle type (fine particles, spherical particles and fibrous particles) in the powder sample is calculated from the medians of the number distribution of the respective LEFI and DIFI for fibrous particles, and the respective EQPC for fine particles and spherical particles. Number distributions are calculated from the DIFI, EQPC and LEFI for each particle within the sample.
- For the purpose of the present invention fine particles have a particle length LEFI of less than 40 micrometers and generally a particle length LEFI of at least 10 micrometers. The detection limit of the QICPIC™ with a M7 optical system is 10 micrometers.
- The volume of the fine particles in a sample of a polysaccharide derivative can be calculated according to Equation 1
wherein V is the volume of fine particles, n is the number of fine particles in the sample and EQPC here is the median EQPC determined from the number particle size distribution of the fine particles. - For the purpose of the present invention a distinction between fibrous particles and other (spherical) particles is made if the particles have a particle length LEFI of more than or equal to 40 micrometers. This distinction is made based on the parameters from the image analysis that describes the shape of the particles; these parameters are elongation, sphericity and aspect ratio as defined above.
- Fibrous particles, as generally understood by the skilled artisan, are typically particles characterized by irregular shape and length typically much larger than the diameter. Fibers can be straight or curved, thin or thick. Consequently, both shape and size information from the QICPIC™ is used to define the fibrous particles. For the purpose of the present invention particles are "fibrous" particles if they meet one of the following definitions I or II: I) particles with an elongation equal or less than 0.35, an aspect ratio of equal or less than 0.45, and a LEFI of equal or greater than 40 micrometers; or II) particles with an elongation equal or less than 0.35, an aspect ratio of greater than 0.45, a sphericity of less than 0.7 and a LEFI of equal or greater than 40 micrometers.
- The volume of fibrous particles in a sample of a polysaccharide derivative can be calculated according to Equation 2
wherein Vf is the volume of fibrous particles, nf is the number of fibrous particles in the sample, DIFI is the median projection area of the particles divided by the sum of all lengths of the branches of the particles determined from the number particle size distribution of the fibrous particles and LEFI is the median particle length determined from the number particle size distribution of the fibrous particles. - For the purpose of the present invention particles meet the definition of "spherical particles" if they have an elongation equal or less than 0.35, and an aspect ratio greater than 0.45, and a sphericity equal or greater than 0.70, and a LEFI equal or greater than 40 micrometers. For the purpose of the present invention particles also meet the definition of "spherical particles" if they have an elongation greater than 0.35 and a LEFI equal or greater than 40 micrometers.
- The volume of the spherical particles in a sample of a polysaccharide derivative can be calculated according to Equation 3
wherein Vs is the volume of spherical particles, ns is the number of spherical particles in the sample and EQPC here is the median EQPC determined from the number particle size distribution of the spherical particles. Alternatively, the volume of the spherical particles can be calculated by subtracting the volume of the fine particles and the volume of the fibrous particles from the total volume of the sample. - The volume fractions can be readily calculated from the volumes V, Vs and Vf as defined above. Since the densities of an individual fine particle, of an individual fibrous particle and of an individual spherical particle are all essentially the same, the volume fractions essentially correspond to the weight fractions.
- In one aspect the polysaccharide derivatives of the present invention have a volume fraction of fine particles of no more than 40%, preferably no more than 35%, more preferably no more than 30% and most preferably no more than 28%. Polysaccharide derivatives of the present invention generally have a volume fraction of fine particles of at least 2%. Moreover, polysaccharide derivatives of the present invention have a volume fraction of fibrous particles of no more than 40%, preferably no more than 30% and more preferably no more than 20%. Typically the polysaccharide derivatives of the present invention have a volume fraction of fibrous particles of one percent or more. It has been found that the volume fraction of fibrous particles in the polysaccharide derivatives of the present invention is smaller than the volume fraction of fibrous particles in known polysaccharide derivatives. Moreover, the sum of the fine particles and of the fibrous particles in the polysaccharide derivatives of the present invention is not more than 50 volume percent, preferably not more than 45 volume percent, more preferably not more than 40 volume percent, most preferably not more than 35 volume percent, and particularly not more than 30 volume percent. Accordingly, polysaccharide derivatives of the present invention have a volume fraction of non-fine and non-fibrous other (i.e., spherical) particles of at least 50%, preferably at least 55%, more preferably at least 60%, most preferably at least 65%, and particularly at least 70%.
- Bulk density as used herein is defined as the ratio of apparent mass to volume of a material taken, called untapped bulk density. A useful procedure for measuring the untapped bulk density is described in the example section. Polysaccharide derivatives which are useful in the present invention generally have an untapped bulk density of more than 150 kg/m3, preferably more than 300 kg/m3, more preferably more than 350 kg/m3, and most preferably 400 kg/m3 or more.
- In another aspect the polysaccharide derivatives of the present invention have a flowability of at least 45 g/sec, preferably at least 50 g/sec, and more preferably at least 60 g/sec. Their flowability generally is up to 90 g/sec, but in ideal cases the flowability can be up to 100 g/sec or even up to 120 g/sec. The flowability as used herein is defined as the amount of the polysaccharide derivative particles that flows out of a flow test apparatus having a vertically arranged column of about 300 mm with a diameter of about 90 mm and a conic shaped bottom geometry having a height of about 110 mm, a vertex angle of about 40° and an outlet diameter of about 50 mm. The flow test apparatus is described in more detail in the examples and is illustrated in
Fig. 1 . Surprisingly the polysaccharide derivatives of the invention have particle flow that exceeds polysaccharide derivatives known in the art with an equivalent bulk density. - The polysaccharide derivatives of the present invention preferably have a median LEFI of from 60 to 350 micrometers, more preferably from 63 to 300 micrometers, most preferably from 65 to 270 micrometers. The median LEFI means that 50% of the LEFI of the particle distribution is smaller than the given value in µm and 50% is larger, as calculated from the volume distribution.
- Preferred polysaccharide derivatives are polysaccharide ethers and polysaccharide esters, more preferably cellulose derivatives, such as cellulose ethers and esters, most preferably water-soluble cellulose ethers. They can have one or more substituents, preferably of the types: hydroxyethyl, hydroxypropyl, hydroxybutyl, methyl, ethyl, propyl, dihydroxypropyl, carboxymethyl, sulfoethyl, hydrophobic long-chain branched and unbranched alkyl groups, hydrophobic long-chain branched and unbranched alkyl aryl groups or aryl alkyl groups, cationic groups, acetate, propionate, butyrate, lactate, nitrate or sulfate, of which some groups, such as, for example, hydroxyethyl, hydroxypropyl, hydroxybutyl, dihydroxypropyl and lactate, are capable of forming grafts. The substituents of the polysaccharides according to the invention are not limited to these groups. Typical polysaccharide derivatives are guar derivatives, starch derivatives, chitin or chitosan derivatives, and preferably cellulose derivatives, but the polysaccharide derivatives according to the invention are not limited to these.
- Examples of cellulose derivatives are hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), ethyl hydroxyethyl cellulose (EHEC), carboxymethyl cellulose, carboxymethyl hydroxyethyl cellulose (CMHEC), hydroxypropyl hydroxyethyl cellulose (HPHEC), methylcellulose (MC), methyl hydroxypropyl cellulose (MHPC), methyl hydroxyethyl cellulose (MHEC), carboxymethyl cellulose (CMC), hydrophobically modified hydroxyethyl cellulose (hmHEC), hydrophobically modified hydroxypropyl cellulose (hmHPC), hydrophobically modified ethyl hydroxyethyl cellulose (hmEHEC), hydrophobically modified carboxymethyl hydroxyethyl cellulose (hmCMHEC), hydrophobically modified hydroxypropyl hydroxyethyl cellulose (hmHPHEC), hydrophobically modified methylcellulose (hmMC), hydrophobically modified methyl hydroxypropyl cellulose (hmMHPC), hydrophobically modified methyl hydroxyethyl cellulose (hmMHEC), hydrophobically modified carboxymethyl methylcellulose (hmCMMC), sulfoethyl cellulose (SEC), hydroxyethyl sulfoethyl cellulose (HESEC), hydroxypropyl sulfoethyl cellulose (HPSEC), methyl hydroxyethyl sulfoethylcellulose (MHESEC), methyl hydroxypropyl sulfoethyl cellulose (MHPSEC), hydroxyethyl hydroxypropyl sulfoethyl cellulose (HEHPSEC), carboxymethyl sulfoethyl cellulose (CMSEC), hydrophobically modified sulfoethyl cellulose (hmSEC), hydrophobically modified hydroxyethyl sulfoethyl cellulose (hmHESEC), hydrophobically modified hydroxypropyl sulfoethyl cellulose (hmHPSEC) or hydrophobically modified hydroxyethyl hydroxypropyl sulfoethyl cellulose (hmHEHPSEC).
- Preferred cellulose derivatives are cellulose esters or cellulose ethers. Preferred cellulose ethers are carboxy-C1-C3-alkyl celluloses, such as carboxymethyl celluloses; carboxy-C1-C3-alkyl hydroxy-C1-C3-alkyl celluloses, such as carboxymethyl hydroxyethyl celluloses; C1-C3-alkyl celluloses, such as methylcelluloses; C1-C3-alkyl hydroxy-C1-3-alkyl celluloses, such as hydroxyethyl methylcelluloses, hydroxypropyl methylcelluloses or ethyl hydroxyethyl celluloses; hydroxy-C1-3-alkyl celluloses, such as hydroxyethyl celluloses or hydroxypropyl celluloses; mixed hydroxy-C1-C3-alkyl celluloses, such as hydroxyethyl hydroxypropyl celluloses, or alkoxy hydroxyethyl hydroxypropyl celluloses, the alkoxy group being straight-chain or branched and containing 2 to 8 carbon atoms. Particularly preferred cellulose derivatives are methylcellulose, methyl hydroxyethyl cellulose, methyl hydroxypropyl cellulose, hydroxypropyl cellulose and carboxymethyl cellulose, particularly in its sodium form. Two or more types of polysaccharide derivatives, preferably cellulose derivatives, more preferably two or more types of cellulose ethers, can be incorporated in combination in the dosage form of the present invention. Particularly, a combination of two different types of hydroxypropyl methylcelluloses or methylcelluloses or a combination of i) a hydroxypropyl methylcellulose or methylcellulose and ii) a carboxymethyl cellulose can be used in combination for preparing the dosage forms of the present invention.
- Most preferably, the water-soluble cellulose ether is a methylcellulose with a methyl degree of substitution DSmethyl of from 1.2 to 2.2, preferably from 1.5 to 2.0; or a hydroxypropyl methylcellulose with a DSmethyl of from 0.9 to 2.2, preferably from 1.1 to 2.0, and an MShydroxypropyl of from 0.02 to 2.0, preferably from 0.1 to 1.2; or a hydroxyethyl methylcellulose with a DSmethyl of from 1.15 to 2.3, preferably from 1.15 to 2.2, and an MShydroxyethyl of from 0.03 to 1.0, preferably from 0.05 to 0.9; or a hydroxyethyl cellulose with an MShydroxyethyl of from 1.2 to 3.0, preferably from 1.45 to 2.2. The determination of the ether side groups, i.e. the DSmethyl, MShydroxyethyl and MShydroxypropyl can be effected as described by K.L. Ketterer, W.E. Kester, D.L. Wiederrich, and J.A. Grover, Determination of Alkoxyl Substitution in Cellulose Ethers by Zeisel-Gas Chromatographie, Analytical Chemistry, Vol. 51, No. 13, Nov 1979, 2172-76.
- The viscosities of the water-soluble cellulose ethers can vary over a broad range. In one aspect of the present invention the viscosity of the cellulose ether is more than 150 mPa·s, preferably from 500 to 200,000 mPa·s, more preferably from 500 to 100,000 mPa·s, most preferably from 1000 to 80,000, particularly from 1000 to 60,000, determined in a 1.5 % by weight aqueous solution at 20 °C in a Haake RS600 rheometer with a cone and plate Geometry (CP-60/2°) at 20 °C and at a shear rate of 2.55 s-1. In another aspect of the present invention the viscosity of the cellulose ether is from 1.2 to 200 mPa·s, preferably from 2 to 100 mPa·s, more preferably from 2.5 to 50 mPa·s, in particular from 3 to 30 mPa·s, measured as a 2 weight-% aqueous solution at 20 °C according to ASTM D2363 - 79 (Reapproved 2006). Such low viscosity cellulose ethers can be produced in a known manner by partial degradation of higher viscosity cellulose ethers.
- The production of polysaccharide derivatives, preferably polysaccharide ethers and polysaccharide esters is known in the art. Typically the production process involves activating the polysaccharide, such as cellulose, for example by treatment with an alkali metal hydroxide, reacting the thus treated polysaccharide with a derivatizing agent, such as an etherifying or esterifying agent, and washing the polysaccharide derivative to remove byproducts. After the washing step the polysaccharide derivative generally has a moisture content of from 30 to 60 percent, typically from 45 to 55 percent, based on the total weight of the moist polysaccharide derivative. While the preferred washing liquor may depend on the specific type of polysaccharide derivative, preferred washing liquors generally are water, isopropanol, acetone, methylethylketone or brine. More preferred washing liquors generally are water or brine. Cellulose derivatives are generally washed at a temperature of from 20 to 120 °C, preferably from 65 to 95 °C. A solvent-moist, preferably a water-moist filter cake is obtained after washing and separating the polysaccharide derivative from the washing liquor. The moist polysaccharide derivative is usually obtained in the shape of moist granules, moist lumps and/or a moist paste. The moist polysaccharide derivative can be directly subjected to a drying-grinding step as described below or, e.g., for logistics reasons, can be subjected to an intermediate drying step.
- Drying-grinding is generally described in the art as drying and grinding simultaneously in one process step with one unit operation, typically an impact mill or an air swept impact mill. Drying is typically accomplished with a combination of hot gas and mechanical energy. Hot air is most commonly used but also hot nitrogen gas can be used. The hot gas and the wet product stream are generally fed via separate inlets into the mill, typically hot gas from the bottom and wet product at a side entrance via a feed screw system connected to the mill. Superheated vapor of a solvent, such as superheated steam, or a steam/inert gas mixture or a steam/air mixture can also be used as heat-transfer gas and transport gas, as described in more detail in European
Patent Applications EP 0 954 536 A1 (equivalent toUS Patent No. 6,320,043 ) andEP 1 127 910 A1 (equivalent toUS Patent No. 7,259,257 ). Preferably the moist polysaccharide derivative is subjected to drying-grinding in a gas-swept impact mill, preferably an air-swept impact mill, wherein the polysaccharide derivative is subjected to an impacting and/or shearing stress. Preferred gas-swept impact mills are Ultra Rotor mills (Altenburger Maschinen Jaeckering, Germany) or Turbofiner PLM mills (PALLMANN Maschinenfabrik GmbH & Co. KG, Germany). Gas classifier mills are also useful gas-swept impact mills, for example, the Hosokawa Alpine Air Classifier mill - ZPS Circoplex Hosokawa Micron Ltd., Cheshire, England. When drying-grinding a moist polysaccharide derivative, the median particle diameter and the bulk density of the polysaccharide derivative can be controlled by controlling the temperature of the polysaccharide derivative prior to drying-grinding, as described in patent applicationPCT/US10/043522, filed 28 July 2010 - The polysaccharide derivative is useful as an excipient for a dosage form, particularly as an excipient for a sustained-release dosage form, which means that it has the function to regulate the release of an active ingredient from the dosage form over an extended period of time. The term "sustained-release" is used herein synonymously to the terms prolonged release; extended release; sustained release; depot release; time release; controlled release; modified release or prolonged action. "Sustained release" is an approach by which active compounds, such as biologically active compounds, are made available at a rate and duration designed to accomplish an intended effect. For example, an oral controlled release drug delivery system is a device or dosage form that regulates the release of a drug into the gastrointestinal tract, thereby controlling the absorption rate of that drug in order to achieve a desired blood plasma profile. These dosage forms are designed to provide a constant or nearly constant drug level in plasma with reduced fluctuation via a slow, continuous release of drug over an extended period of time. In the sustained-release dosage form of the present invention it generally takes between 0.75 and 36 hours, more preferably between 4 and 30 hours, and most preferably between 8 and 24 hours to release the active ingredient from the dosage form in its entirety.
- The above-described polysaccharide derivatives are useful as an excipient for dosage forms, particularly for sustained-release dosage forms in a variety of technological fields, for example in personal care, laundry care or agricultural applications, water treatment, and particularly in human or animal health care applications, most specifically pharmaceutical applications wherein a biologically active ingredient is selected from vitamins, herbal and mineral supplements and drug substances.
- The above-described polysaccharide derivatives have a unique combination of features which makes them very useful as an excipient in dosage forms, for example in pharmaceutical dosage forms. The polysaccharide derivatives have good flow properties. They can be efficiently blended with a biologically active ingredient, and, if desired, with one or more optional adjuvants, even in the absence of a substantial amount of added solvent or heat. It is to be understood that one or more types of the above-described polysaccharide derivatives and one or more types of active ingredients can be blended with one or more optional adjuvants to prepare a dosage form. Preferably the blending process is conducted at about room temperature.
- A large variety of active ingredients are useful, dependent on the intended end-use of the dosage form. Active ingredients are known in the art and include, among others, detergents or surfactants for laundry care applications; fertilizers, herbicides or pesticides in formulations designed to release the bioactive agents over a prolonged period of time in agricultural applications. A wide range of biologically active ingredients are useful, such as vitamins, herbals and mineral supplements and drugs. The biologically active ingredient includes hydrophobic, hydrophilic and amphiphilic compounds. The biologically active ingredient may be used for treating indications such as, by way of example and without limitation, inflammation, gout, hypercholesterolemia, microbial infection, AIDS, tuberculosis, fungal infection, amoebic infection, parasitic infection, cancer, organ rejection, diabetes, heart failure, arthritis, asthma, pain, congestion, urinary tract infections, vaginal infection, seizure-related disorders, depression, psychosis, convulsion, diabetes, blood coagulation, hypertension and birth control. The amount of the biologically active ingredient loaded into a pharmaceutical dosage form will vary according to the pharmacological activity of the compound, the indication being treated, the targeted dosing regimen, the projected method of administration, the integrity or stability of the final composition or other such reasons.
- The amount of the active ingredient generally is at least 0.5 percent, preferably at least 1 percent, more preferably at least 5 percent, most preferably at least 10 percent, based on the total weight of the dosage form, and generally up to 75 percent, preferably up to 65 percent, more preferably up to 55 percent, most preferably up to 45 percent, based on the total weight of the dosage form. The active ingredient is generally solid and preferably has a median particle diameter as defined further above of from 1 to 500 micrometers. Useful optional adjuvants are known in the art and are generally solid, such as one or more fillers, pigments, colorants, flavorants, disintegrating agents, binders, plasticizers, salts, acidic and basic pH modifiers, antioxidants and/or lubricants. Examples of such adjuvants are acacia, corn starch, guar gum, potato starch, alginic acid, stearic acid, magnesium stearate, lactose, sucrose, dicalcium phosphate, microcrystalline cellulose, sugars, minerals, cellulose powder or cellulose fibers. Optional adjuvants are generally solid and preferably have a median particle diameter as defined further above of from 1 to 500 micrometers.
- The blend of one or more types of polysaccharide derivatives, one or more active ingredients and one or more optional adjuvants has good flow properties and exhibits a minimum of segregation which means that the blend shows excellent uniformity. By this it is meant that if the blend is divided into portions, the content of the active ingredient is essentially the same in all portions. The blend can be directly filled into capsules or can be subjected to a direct compression process to produce tablets or similar dosage forms. The efficient feeding of the blend to a capsule filling device or to a compression device allows for uniform weights of the dosage forms. The combination of good powder flow and high bulk density, generally minimum segregation and good compactibility allows the blend to be efficiently processed to a dosage form in a direct compression process, even in the absence of a substantial amount of added solvent, heat, pressure or additional processing steps. By the term "in the absence of a substantial amount of added solvent or heat" is meant that solvent or heat is not added in a sufficient amount to the blend of the active ingredient and the polysaccharide derivative to effect granulation of the blend. Preferably the direct compression process is conducted in the absence of any amount of added solvent or heat.
- Direct compression processes to produce tablets are known in the art. Typically a compaction pressure of from 150 MPa to 375 MPa, preferably from 200 to 300 MPa is sufficient to produce tablets of good quality. The direct compression process of the present invention eliminates the need for formulators of dosage forms to subject the blend of one or more polysaccharide derivatives, one or more active ingredients and one or more optional adjuvants to a wet granulation step before compressing the blend to a tablet. A wet granulation step involves wetting, drying and screening steps, which is not desirable for moisture-sensitive or heat-sensitive drugs. The direct compression process of the present invention also eliminates the need for a complicated dry-granulation process. In addition, products made by the direct compression process are less costly than those produced when wet or dry granulation processes are employed.
- It has surprisingly been found that sustained release pharmaceutical dosage forms with excellent drug release profiles can be produced when using the polysaccharide derivatives of the present invention, which have a better flowability than the cellulose ethers recommended for sustained release pharmaceutical dosage forms in
U.S. Patent No. 4,734,285 and which have an improved flowability and/or an increased bulk density, as compared to the cellulose ethers disclosed inWO 2008/127794 . - The polysaccharide derivatives of the present invention can form at least a portion of a coating, particularly a compression coating, of a dosage form to control the release of the active ingredient. However, more preferably the granular material forms at least a portion of the matrix of a dosage form.
- The open-ended terms "comprising," and "comprises," are synonymous with "including," "having," and "characterized by". When referring to a preceding list of elements or steps (e.g., ingredients), the phrases "combination thereof," "mixture thereof," and the like mean any two or more (at least two) up to and including all of the listed elements or steps. The term "optionally" means "with or without" (e.g., "optionally, an additive" means with or without an additive).
- Unless otherwise mentioned, all parts and percentages are by weight. Viscosities of the cellulose ethers are measured as a 2 weight percent aqueous solution using a Brookfield LVT viscosimeter at 20 °C.
- The following cellulose ethers listed in Table 1 below are used in the Examples:
- K15MFG: A Food Grade hydroxypropyl methylcellulose commercially available from The Dow Chemical Company as METHOCEL™ K15MFG cellulose ether.
- K4MFG: A Food Grade hydroxypropyl methylcellulose commercially available from The Dow Chemical Company as METHOCEL™ K4MFG cellulose ether.
- K100M: Hydroxypropyl methylcellulose commercially available from The Dow Chemical Company as METHOCEL™ K100M cellulose ether.
- E15LV: Hydroxypropyl methylcellulose commercially available from The Dow Chemical Company as METHOCEL™ E15LV cellulose ether.
- K100M DOM: Hydroxypropyl methylcellulose which is produced in the same manner and has the same degree of substitution as the commercially available METHOCEL™ K100M cellulose ether, except that K100M DOM is a material that has not been ground after production but is a dryer outlet material that is directly used in Examples 15-17 for producing the cellulose ether of the present invention.
- Percent methoxyl and hydroxypropyl substitution and viscosities of the Cellulose ethers are summarized below.
Commercial Name % Methoxyl % Hydroxypropyl Viscosity (mPas) METHOCEL K100M Premium CR 22.0 - 24.0 9.5 - 11.5 75,000 - 140,000 METHOCEL K100M Premium DC 22.0 - 24.0 9.5 - 11.5 75,000 - 140,000 METHOCEL K15M Food Grade 19.0 - 24.0 7.0 - 12.0 11,250 - 21,000 METHOCEL K4M Food Grade 19.0 - 24.0 7.0 - 12.0 3,000 - 5,600 METHOCEL E15 Food Grade 28.0 - 30.0 7.0 - 12.0 12 - 18 - CRT20000PA: Sodium carboxymethyl cellulose powder having a degree of DS(carboxymethyl) of 0.65 - 0.95 and a viscosity of about 20000 mPa·s. The sodium carboxymethyl cellulose powder is commercially available from Dow Wolff Cellulosics (a subsidiary of The Dow Chemical Company) as Walocel™ C CRT20000PA.
- A commercially available continuous compounder with heating and cooling jacket is used to add water to dry cellulose ether. The compounder jacket is supplied with a fluid of -10 °C to 70 °C. Cellulose ether at a moisture level of less than 5 % is fed continuously at a feed rate of 10-30 kg/h into the compounder. Water of a temperature of 5 °C to 20 °C is continuously added at rates of 1-120 kg/h to the compounder resulting in a moisture level of about 50-82 %. The more specific reaction conditions are listed in Table 1 below. The wet product is transported continuously via a transport belt into a mill feed unit (Altenburger Maschinen Jaeckering GmbH, Hamm, Germany). The bottom blades of the vessel agitator press the paste into a single augur screw mounted at the bottom of the vessel. The wet product is forced through a perforated plate directly into the side of an Ultrarotor II "S" impact mill (Altenburger Maschinen Jaeckering GmbH, Hamm, Germany) between the first and second grinding stage. The mill is equipped with seven grinding stages. The bottom three grinding stages are equipped with standard grinding bars. Turbo-bars are installed in the top four grinding stages. A co-rotating finger sifter wheel with twelve blades is installed on the top of the 7th grinding stage. The interior of mill jacket has the standard Altenburger corrugated stationary grinding plates.
- The rotor of the impact mill is operated at a circumferential speed of 91 or 114 m/s. A hot nitrogen stream is fed at a rate listed in Table 1 below into the bottom of the mill. A cyclone is used to separate the dried product from the nitrogen. The final product moisture is smaller than 3 % by weight.
- Hydroxypropyl methylcellulose ether having a degree of substitution of methoxyl groups of 22.6% and of hydroxypropoxyl groups of 10.3 %, and a viscosity of 114,700 Pa.s, is used as a comparative material. It is representative of state of the art controlled release grade cellulose ether and referred to as CR cellulose ether. The production of controlled release grade cellulose ethers is disclosed in
U.S. Patent No. 4,734,285 . - Hydroxypropl methylcellulose ether having a degree of substitution of methoxyl groups of 22.7% and of hydroxypropoxyl groups of 10.0% , and a viscosity of 103,300mPa.s, is used as a comparative material. The hydroxypropyl methylcellulose of Comparative Example B can be produced by a granulation process as described in WO 2008/127794. The hydroxypropyl methylcellulose of Comparative Example B is referred to as "Direct Compression" (DC) cellulose ether.
Table 1 (Comparative) Example Cellulose Ether (CE) A Cellulose Ether (CE) B Wt. % A/B Brookfield Viscosity [mPa·s] Moisture Wet CE [%] Water Temperature [°C] Temperature of wet CE [°C] Nitrogen Flow Mill [m3/hr] Mill Blade Tip Speed [m/s] 1 K15MFG E15LV 25/75 99.0 65 19 61 715 114 2 K15MFG E15LV 25/75 202.0 50 19 60 1376 114 3 K15MFG E15LV 25/75 104.0 65 16 21 667 114 4 K15MFG E15LV 25/75 182.0 59 14 40 1071 114 5 K15MFG E15LV 25/75 116.0 51 20 61 561 114 6 K15MFG E15LV 25/75 129.0 58 20 42 896 114 7 K15MFG E15LV 25/75 179.0 66 13 19 1415 114 8 K4MFG CRT20000PA 20/80 *) 71 5 30 1002 114 9 K4MFG CRT20000PA 50/50 *) 59 5 40 1069 114 10 K4MFG CRT20000PA 50/50 *) 59 5 40 991 114 11 K4MFG CRT20000PA 80/20 *) 68 5 59 979 114 12 K4MFG CRT20000PA 20/80 *) 67 5 61 936 114 13 K100M - 100 89200 67 5 22 1900 114 14 K100M - 100 91400 76 7 19 1030 91 15 K100M_DOM - 100 147600 65 6 40 1051 114 16 K100M_DOM - 100 151500 80 11 40 987 114 17 K100M_DOM - 100 133900 80 11 20 565 114 A (CR) K100M CR - 100 114,700 - - - - - B (DC) K100M DC - 100 103,300 - - - - - *) not measured - The DIFI, Equivalent Projected Circle Diameter (EQPC), length (LEFI), elongation, aspect ratio and sphericity of the particles in the powder samples of Examples 1-17 and Comparative Examples A and B are measured or calculated with a high speed image analyzer (high speed image analyzer sensor QICPIC, Sympatec, Germany, with dry disperser RODOS/L with an inner diameter of 4 mm and dry feeder VIBRI/L and divide Software WINDOX5, Vers. 5.3.0 and M7 lens). The volume percentages of fine particles, fibrous particles, and other (spherical) particles are calculated from these parameters as described further above and listed in Table 2 below. The median EQPC (50% of the EQPC of the particle distribution is smaller than the given value in µm and 50% is larger, as calculated from the volume distribution) and the median LEFI (50% of the LEFI of the particle distribution is smaller than the given value in µm and 50% is larger, as calculated from the volume distribution) are also listed in Table 2 below.
- Particle flowability is measured by a flow test method. The apparatus for the flow test method consists of two Plexiglass pieces, specifically a cylindrical part (column) which is 305 mm tall with an inner diameter of 89 mm; and a conical part (a vertex down cone) with a height of 108 mm, a top diameter of 89 mm and an outlet diameter (orifice) of 51 mm. The vertex angle ϕ of the cone is 39.2 °. By all diameters the inner diameters are meant, excluding the wall thickness. A schematic illustration of the apparatus for the flow test method is illustrated in
Figure 1 . The vertex angle ϕ of the right circular vertically inverted cone (i.e. vertex down cone) is the angle made by a cross section through the vertex and the center of the base. The total volume of the tester is 2.32 liters. The two pieces are connected. The tester is set up vertically with the vertex of the cone at the bottom. The particle flow rate is measured by first blocking the outlet of the cone with a plate, and then filling the tester completely with non-compacted polysaccharide derivative in particulate form by pouring the polysaccharide derivative into the top of the cylinder and filling the cylinder completely. The polysaccharide derivative is discharged from the hopper into a collection container by removing the plate. A timer is used to record the total time for the particles to discharge from the hopper. The polysaccharide derivative in the collection container is then weighed and the time and weight are recorded. The flowability, also designated as flow rate, is calculated as the ratio of the weight of polysaccharide derivative per unit time. Each material is tested four times and the average flow rate is recorded. - The untapped bulk density of the polysaccharide derivative in particulate form is measured using a Hosokawa Powder Characteristics Tester: Model PT-N available from Hosokawa Micron, Osaka Japan.
Table 2 (Comparative) Example Median LEFI [microns] Median EQPC [microns] Bulk Density [kg/m3] Flowability [g/s] Fine particles [% volume] Fibrous particles [% volume] Other (spherical) particles [% volume] 1 77.8 58.86 337 106 12.8 1.9 85.3 2 123.34 72.13 312 56 7.4 8.4 84.2 3 93.88 65.11 399 66 9.1 3.8 87.1 4 103.25 68.1 330 72 7.6 4.9 87.5 5 66.0 48.2 375 76.8 28.1 2.3 69.6 6 84.23 62.94 351 77 7.3 2.4 90.4 7 178.34 95.07 399 84 3.4 13.5 83.2 8 87.6 54.3 503 73.5 16.0 6.0 78.0 9 122.6 58.1 413 68.9 14.0 12.0 74.0 10 129.2 59.5 416 72.0 13.0 13.0 74.0 11 141.7 64.2 373 60.4 11.0 13.0 76.0 12 100.6 52.9 478 59.3 20.0 8.0 72.0 13 253.7 119.3 276 80.8 2.5 28.4 69.1 14 165.0 88.8 327 86.0 4.2 14.1 81.7 15 266.9 75.9 377 64.3 5.4 19.2 75.4 16 151.0 60.5 441 60.3 12.6 5.5 81.9 17 82.5 51.7 495 85.9 23.2 2.2 74.6 A (CR) 264.6 93.3 302 31.9 4.9 41.1 54.0 B (DC) 395.3 152.5 164 43 2.5 46.4 51.2 - Table 2 illustrates the improved flowability, and in the preferred embodiments of the present invention also the higher bulk density, of the polysaccharide derivatives of the present invention, as compared to the known polysaccharide derivatives of comparative Examples A and B.
- The controlled drug release performance using a Ketoprofen dosage form is determined after 3 and 12 hours. Ketoprofen, hydroxypropyl methylcellulose, and impalpable lactose as listed in Table 3 are blended in a Turbula jar blender for 10 minutes. Magnesium stearate is added and the pharmaceutical composition blended for an additional 1 minute. The resulting formulated system is fed into a Manesty BETA tablet press with a target tablet weight of 400mg. The tooling used in the press is 10.3 mm in diameter round, flat-faced and bevel-edged. The tablet press is set at a speed of 12-14 RPM (revolutions per minute) and the tablets are compressed at a target compression force of 5000 lbs (22.2 kN), producing a compaction pressure of 266 MPa.
Table 3 Ingredients Manufacturer Wt % hydroxypropyl methylcellulose The Dow Chemical Company, USA 30 Ketoprofen Spectrum Chemicals, USA 20 Impalpable Lactose Sheffield, USA 49 Magnesium Stearate Mallinckrodt, USA 1 - Tablets are allowed to relax for 24 hours before testing. Each tablet is weighted using an analytical balance and then each tablet is crushed using a HT-300 Hardness tester. The sustained release performance of the tablets is also compared. The release of ketoprofen is measured using 6 tablets from each formulation. Drug release is measured using a commercially available Varian Total Solution with Dual VK 7025 dissolution system. A USP Type II dissolution apparatus is used to determine drug release performance. The paddle stirring rate is set to 50 RPM and the dissolution media, maintained at 37°C, is 0.05M phosphate buffer at a pH of 5.8. Detection of dissolved ketoprofen is achieved using ultraviolet absorption spectrometry at a wavelength of 260nm.
- As shown in
Figure 2 , the drug release profiles of ketoprofen from tablets produced from compositions comprising the novel cellulose ethers of Examples 13, 14, 15, 16, and 17 as excipients show similar drug release as tablets produced from compositions comprising the CR grade or DC grade cellulose ethers of Comparative Examples A and B. - Metoprolol tartrate, microcrystalline cellulose and Starch 1500® are blended as listed in Table 4 below in a V-blender for 10 minutes to prepare a pharmaceutical formulation. Magnesium stearate is added and the pharmaceutical composition is blended for an additional 1 minute.
Table 4 Ingredients Manufacturer Wt % hydroxypropyl methylcellulose The Dow Chemical Company, USA 30 Metoprolol Tartrate (active ingredient) Mulji Mehta & Sons, Private Ltd, India 10 Avicel Microcrystalline Cellulose (PH 102) FMC Biopolymers, USA 49.5 Starch 1500® Colorcon, USA 10 Magnesium Stearate Mallinckrodt, USA 0.5 - The metoprolol tartrate compositions are compressed into tablets according to a direct compression process. The tablets are made using a Manesty BETA tablet press with a target tablet weight of 400mg. The tooling used in the press is 10.3 mm in diameter round, flat-faced and bevel-edged. The tablet press is set at a speed of about 17 RPM (revolutions per minute) and the tablets are compressed at a target compression force of 5000 lbs (22.2 kN), producing a compaction pressure of 266 MPa. The formulations are tableted with each run lasting about 45 minutes. Tablets are allowed to relax for 24 hours before testing. Each tablet is weighted using an analytical balance and then each tablet is crushed using a HT-300 Hardness tester.
- Table 5 below illustrates the comparison of properties of tablets produced from compositions comprising cellulose ethers listed in Table 5 below. Metoprolol tartrate formulations made using cellulose ethers of the present invention achieve the target tablet weight and show less tablet to tablet weight variability than those made from the formulations made using CR or DC grade cellulose ethers of Comparative Examples A or B. Achieving the target tablet weight and less tablet to tablet variability is an indication of the superior bulk density and flow properties of the cellulose ethers of the present invention. Moreover, tablets produced from formulations comprising cellulose ethers of the present invention also have a significantly higher average tablet weight when compared to tablets produced from formulations comprising cellulose ethers of Comparative Example B.
Table 5 Cellulose Ether Average Tablet Weight (mg) Standard Deviation Hardness (SCU) Standard Deviation Comp. Ex. A (CR) 409.5 12.82 22.6 1.67 Comp. Ex. B (DC) 374.7 5.23 19.0 0.73 Ex. 13 411.8 3.70 21.6 1.10 Ex. 14 412.3 4.17 18.9 0.77 Ex. 15 418.6 5.11 19.3 0.74 - Table 5 also shows a comparison of tablet average hardness values for the metoprolol tartrate formulations. Tablets produced from formulations comprising cellulose ethers of the present invention show less variability in tablet to tablet hardness than tablets produced from formulations comprising known cellulose ethers of Comparative Example A.
- The sustained release performance of the tablets are also compared. The release of metoprolol tartrate is measured using 6 tablets from each formulation. The tablets are dissolved in deionized water at 37°C, USP II Apparatus at 50 rpm, using a commercially available Varian Total Solution with Dual VK 7025 dissolution system. As shown in
Figure 3 , the drug release profiles of metoprolol tartrate from tablets produced from compositions comprising the novel cellulose ethers of Examples 13, 14 or 15 as excipients show similar drug release as tablets produced from compositions comprising the known cellulose ethers of Comparative Example A or B.
Claims (15)
- A polysaccharide derivative having a median Equivalent Projected Circle Diameter (EQPC) of less than 140 micrometers and a particle size and shape distribution meeting condition A or B or both:A. non-compacted polysaccharide derivative particles have a flowability of at least 45 g/sec through a vertically inverted cone having a vertex angle of about 40° and an outlet diameter of about 50 mm, orB. i) no more than 40 volume percent of the polysaccharide derivative particles are fine particles having a particle length LEFI of less than 40 micrometers and ii) no more than 40 volume percent of the polysaccharide derivative particles are fibrous particles, and the sum of the fine particles and the fibrous particles does not exceed 50 volume percent.
- The polysaccharide derivative of claim 1 having a particle size and shape distribution such that non-compacted polysaccharide derivative particles have a flowability of at least 50 g/sec.
- The polysaccharide derivative of claim 1 or 2 having a particle size and shape distribution such that i) no more than 30 volume percent of the particles are fine particles having a particle length LEFI of less than 40 micrometers and ii) no more than 30 volume percent of the particles are fibrous particles, and the sum of the fine particles and fibrous particles does not exceed 40 volume percent.
- The polysaccharide derivative of any one of claims 1 to 3 having a median Equivalent Projected Circle Diameter (EQPC) of no more than 130 micrometers.
- The polysaccharide derivative of any one of claims 1 to 4 having an untapped bulk density of more than 0.35 kg/m3.
- The polysaccharide derivative of any one of claims 1 to 5 being a cellulose ether or cellulose ester.
- A dosage form produced froma) one or more polysaccharide derivatives,b) one or more active ingredients, andc) one or more optional adjuvants,wherein said one or more polysaccharide derivatives have a median Equivalent Projected Circle Diameter (EQPC) of less than 140 micrometers and a particle size and shape distribution meeting condition A or B or both:A. non-compacted polysaccharide derivative particles have a flowability of at least 45 g/sec through a vertically inverted cone having a vertex angle of about 40° and an outlet diameter of about 50 mm, orB. i) no more than 40 volume percent of the polysaccharide derivative particles are fine particles having a particle length LEFI of less than 40 micrometers and ii) no more than 40 volume percent of the polysaccharide derivative particles are fibrous particles, and the sum of the fine particles and the fibrous particles does not exceed 50 volume percent.
- The dosage form of claim 7 produced from one or more polysaccharide derivatives set forth in any one of claims 1 to 6, one or more active ingredients, and one or more optional adjuvants.
- The dosage form of claim 7 or 8 being a compressed dosage form wherein the polysaccharide derivative forms at least a portion of the matrix of the dosage form.
- The dosage form of claim 7 or 8 wherein the polysaccharide derivative forms at least a portion of the coating of the dosage form.
- The dosage form of any one of claims 7 to 10 being a sustained-release dosage form.
- A process for preparing a dosage form comprising the step ofI.) blending one or more polysaccharide derivatives, one or more active ingredients, and one or more optional adjuvants, andII.) compressing the blend to a dosage form,
wherein said one or more polysaccharide derivatives have a median Equivalent Projected Circle Diameter (EQPC) of less than 140 micrometers and a particle size and shape distribution meeting condition A or B or both:A. non-compacted polysaccharide derivative particles have a flowability of at least 45 g/sec through a vertically inverted cone having a vertex angle of about 40° and an outlet diameter of about 50 mm, orB. i) no more than 40 volume percent of the polysaccharide derivative particles are fine particles having a particle length LEFI of less than 40 micrometers and ii) no more than 40 volume percent of the polysaccharide derivative particles are fibrous particles, and the sum of the fine particles and the fibrous particles does not exceed 50 volume percent. - The process of claim 12 wherein in step I.) one or more polysaccharide derivatives, one or more active ingredients, and one or more optional adjuvants are blended in the absence of a substantial amount of added solvent or heat.
- The process of claim 12 or 13 wherein one or more polysaccharide derivatives set forth in any one of claims 2 to 6, one or more active ingredients, and one or more optional adjuvants are blended.
- Use of a polysaccharide derivative of any one of claims 1 to 6 for producing a dosage form.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161472224P | 2011-04-06 | 2011-04-06 | |
PCT/US2012/031106 WO2012138529A1 (en) | 2011-04-06 | 2012-03-29 | Novel polysaccharide derivatives and dosage forms |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2694110A1 EP2694110A1 (en) | 2014-02-12 |
EP2694110B1 true EP2694110B1 (en) | 2015-02-11 |
EP2694110B2 EP2694110B2 (en) | 2022-06-08 |
Family
ID=45953271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12714149.7A Active EP2694110B2 (en) | 2011-04-06 | 2012-03-29 | Novel polysaccharide derivatives and dosage forms |
Country Status (8)
Country | Link |
---|---|
US (1) | US8992987B2 (en) |
EP (1) | EP2694110B2 (en) |
JP (1) | JP5731708B2 (en) |
KR (1) | KR101916010B1 (en) |
CN (1) | CN103501817B (en) |
BR (1) | BR112013022431B1 (en) |
MX (1) | MX337827B (en) |
WO (1) | WO2012138529A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX337827B (en) | 2011-04-06 | 2016-03-22 | Dow Global Technologies Llc | Novel polysaccharide derivatives and dosage forms. |
US10143206B2 (en) | 2012-09-27 | 2018-12-04 | Dow Global Technologies Llc | Methods for reducing oil and/or fat uptake of fried foods |
EP2900081B1 (en) * | 2012-09-27 | 2017-02-08 | Dow Global Technologies LLC | Methods for reducing oil and / or fat uptake of fried foods |
BR112015004913B1 (en) * | 2012-09-27 | 2020-10-06 | Dow Global Technologies Llc. | EDIBLE COMPOSITION, METHOD FOR PREPARING A SWEET FOOD, METHOD FOR PREPARING A FOOD PREPARATION CONTAINING FORMED STARCH, METHOD OF REDUCING OIL ABSORPTION OR METHOD OF REDUCING PREPARED FOOD ABSORPTION. CONTAINING STARCH |
EP2837391B1 (en) | 2013-08-12 | 2017-05-10 | Shin-Etsu Chemical Co., Ltd. | Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate |
JP2016122227A (en) * | 2014-12-24 | 2016-07-07 | 株式会社東芝 | Memory system and information processing system |
KR102469464B1 (en) | 2016-10-07 | 2022-11-22 | 신에쓰 가가꾸 고교 가부시끼가이샤 | Low-substituted hydroxypropyl cellulose, production method thereof, and solid preparation |
KR102519854B1 (en) * | 2016-10-07 | 2023-04-10 | 신에쓰 가가꾸 고교 가부시끼가이샤 | Hydroxyalkyl alkyl cellulose, method for producing the same, and solid preparation |
KR102519850B1 (en) | 2016-10-07 | 2023-04-10 | 신에쓰 가가꾸 고교 가부시끼가이샤 | Hydroxyalkyl alkyl cellulose, method for producing the same, and solid preparation |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB804306A (en) | 1956-12-13 | 1958-11-12 | Dow Chemical Co | Method of preparing cellulose ethers readily soluble in cold water |
DE2620461A1 (en) | 1976-05-08 | 1977-11-24 | Kloeckner Humboldt Deutz Ag | MAIN DRYING SYSTEM |
JPS5420126A (en) * | 1977-07-12 | 1979-02-15 | Asahi Chem Ind Co Ltd | Pharmaceutical composition |
AU508480B2 (en) * | 1977-04-13 | 1980-03-20 | Asahi Kasei Kogyo Kabushiki Kaisha | Microcrystalline cellulose excipient and pharmaceutical composition containing thesame |
JPS53127553A (en) * | 1977-04-13 | 1978-11-07 | Asahi Chem Ind Co Ltd | Vehicle |
US4650716A (en) | 1985-05-14 | 1987-03-17 | Hercules Incorporated | Novel salts of carboxymethylcellulose |
US4734285A (en) | 1985-10-28 | 1988-03-29 | The Dow Chemical Company | Sustained release compositions |
DE3839831A1 (en) | 1988-11-25 | 1990-05-31 | Hoechst Ag | METHOD AND DEVICE FOR PRODUCT-FRIENDLY GRINDING AND SIMULTANEOUS DRYING OF DAMP CELLULOSE ETHERS |
WO1992003167A1 (en) † | 1990-08-24 | 1992-03-05 | Shin-Etsu Chemical Co., Ltd. | Coating base for pharmaceutical film and production thereof |
DE4140689B4 (en) | 1991-12-10 | 2007-11-22 | Boehringer Ingelheim Kg | Inhalable powders and process for their preparation |
GB2262527A (en) † | 1992-07-02 | 1993-06-23 | Dow Deutschland Inc | Process for grinding cellulose compounds |
JP2686215B2 (en) † | 1993-04-28 | 1997-12-08 | 信越化学工業株式会社 | Sustained-release tablets |
US5488104A (en) | 1994-06-30 | 1996-01-30 | The Dow Chemical Company | Process for comminuting cellulose ethers |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
EP0824107A3 (en) | 1996-08-12 | 1998-04-22 | Lenzing Aktiengesellschaft | Cellulose particles |
US6320043B1 (en) | 1997-01-21 | 2001-11-20 | Wolf Walsrode Ag | Process for preparing fine-particle polysaccharide derivatives |
GB9802201D0 (en) | 1998-02-03 | 1998-04-01 | Cerestar Holding Bv | Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules |
DE10009409A1 (en) † | 2000-02-28 | 2001-08-30 | Wolff Walsrode Ag | Production of water-soluble cellulose derivatives as fine powder, for use as e.g. paint binders or thickeners, involves dissolution or swelling in water and drying with heat transfer-carrier gas in a high-speed rotary impact mill |
DE10009411A1 (en) | 2000-02-28 | 2001-08-30 | Wolff Walsrode Ag | Process for the preparation of pulverulent water-soluble cellulose derivatives using a steam / inert gas mixture or steam / air mixture as transport and heat transfer gas |
CN101961317A (en) | 2001-07-06 | 2011-02-02 | 生命周期药物公司 | Controlled agglomeration |
PT2708225T (en) * | 2004-04-23 | 2019-05-21 | Cydex Pharmaceuticals Inc | Dpi formulation containing sulfoalkyl ether cyclodextrin |
US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
PT2335707E (en) | 2005-10-26 | 2015-09-10 | Cydex Pharmaceuticals Inc | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
BRPI0809282B8 (en) * | 2007-04-13 | 2021-05-25 | Dow Global Technologies Inc | granular material, starting material for a dosage form, dosage form, direct compression process to prepare a dosage form, use of granular material, and process to granulate a polymer powder |
WO2009015880A1 (en) | 2007-07-31 | 2009-02-05 | Cargill, Incorporated | Direct compressible dextrose |
WO2010106555A2 (en) | 2009-03-17 | 2010-09-23 | Shantilal, Doshi, Bimalkumar | Directly compressible pre-granulated cellulose ether polymer and process for preparing the same |
TWI400089B (en) * | 2009-11-24 | 2013-07-01 | Nippon Soda Co | Hydroxyalkyl cellulose fine particles |
EP2598121B1 (en) | 2010-07-28 | 2018-08-08 | Dow Global Technologies LLC | A method of controlling the release of an active ingredient from a dosage form |
EP2598557B1 (en) | 2010-07-28 | 2019-03-20 | Dow Global Technologies LLC | A process for dry-grinding a polysaccharide derivative |
KR20180132952A (en) * | 2011-04-06 | 2018-12-12 | 다우 글로벌 테크놀로지스 엘엘씨 | Process for producing cellulose derivatives of high bulk density and good flowability |
JP6034365B2 (en) * | 2011-04-06 | 2016-11-30 | ダウ グローバル テクノロジーズ エルエルシー | A method for producing a cellulose derivative having high bulk density, good fluidity and improved cold water dispersibility. |
MX337827B (en) | 2011-04-06 | 2016-03-22 | Dow Global Technologies Llc | Novel polysaccharide derivatives and dosage forms. |
-
2012
- 2012-03-29 MX MX2013011586A patent/MX337827B/en active IP Right Grant
- 2012-03-29 US US14/009,435 patent/US8992987B2/en active Active
- 2012-03-29 EP EP12714149.7A patent/EP2694110B2/en active Active
- 2012-03-29 WO PCT/US2012/031106 patent/WO2012138529A1/en active Application Filing
- 2012-03-29 CN CN201280022115.XA patent/CN103501817B/en active Active
- 2012-03-29 BR BR112013022431-2A patent/BR112013022431B1/en active IP Right Grant
- 2012-03-29 JP JP2014503688A patent/JP5731708B2/en active Active
- 2012-03-29 KR KR1020137026356A patent/KR101916010B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
JP5731708B2 (en) | 2015-06-10 |
KR20140009452A (en) | 2014-01-22 |
MX2013011586A (en) | 2013-12-09 |
JP2014510137A (en) | 2014-04-24 |
BR112013022431B1 (en) | 2019-10-08 |
EP2694110A1 (en) | 2014-02-12 |
EP2694110B2 (en) | 2022-06-08 |
CN103501817A (en) | 2014-01-08 |
US8992987B2 (en) | 2015-03-31 |
KR101916010B1 (en) | 2018-11-08 |
CN103501817B (en) | 2015-07-15 |
MX337827B (en) | 2016-03-22 |
US20140017326A1 (en) | 2014-01-16 |
BR112013022431A2 (en) | 2016-12-06 |
WO2012138529A1 (en) | 2012-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2694110B1 (en) | Novel polysaccharide derivatives and dosage forms | |
JP5977331B2 (en) | Method for producing cellulose derivative having high bulk density and good fluidity | |
US9655851B2 (en) | Granular material for dosage forms | |
JP6928530B2 (en) | Hydroxyalkylalkylcellulose and its production method and solid preparation | |
KR101136659B1 (en) | Solid preparation comprising solid dispersion and method for producing the same | |
US9693960B2 (en) | Method of controlling the release of an active ingredient from a dosage form | |
Di Pretoro et al. | Optimisation and scale-up of a highly-loaded 5-ASA multi-particulate dosage form using a factorial approach | |
JP2017165724A (en) | Solid preparation containing alkyl cellulose and method of producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20131021 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602012005237 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0047380000 Ipc: A61K0047360000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/36 20060101AFI20140917BHEP |
|
INTG | Intention to grant announced |
Effective date: 20141009 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 4 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 709697 Country of ref document: AT Kind code of ref document: T Effective date: 20150315 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012005237 Country of ref document: DE Effective date: 20150326 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20150211 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 709697 Country of ref document: AT Kind code of ref document: T Effective date: 20150211 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150511 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150512 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150611 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R026 Ref document number: 602012005237 Country of ref document: DE |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
26 | Opposition filed |
Opponent name: SHIN-ETSU CHEMICAL CO., LTD. Effective date: 20151111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150331 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150331 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
PLAF | Information modified related to communication of a notice of opposition and request to file observations + time limit |
Free format text: ORIGINAL CODE: EPIDOSCOBS2 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
PLBB | Reply of patent proprietor to notice(s) of opposition received |
Free format text: ORIGINAL CODE: EPIDOSNOBS3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20120329 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
RIC2 | Information provided on ipc code assigned after grant |
Ipc: A61K 47/36 20060101AFI20170523BHEP Ipc: A61K 9/20 20060101ALI20170523BHEP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150611 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
APAH | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNO |
|
APBM | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOSNREFNO |
|
APBP | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2O |
|
APBM | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOSNREFNO |
|
APBP | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2O |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150329 |
|
APBQ | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3O |
|
APBQ | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3O |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150211 |
|
APBU | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9O |
|
PLAY | Examination report in opposition despatched + time limit |
Free format text: ORIGINAL CODE: EPIDOSNORE2 |
|
PLBC | Reply to examination report in opposition received |
Free format text: ORIGINAL CODE: EPIDOSNORE3 |
|
PLAY | Examination report in opposition despatched + time limit |
Free format text: ORIGINAL CODE: EPIDOSNORE2 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602012005237 Country of ref document: DE Representative=s name: MURGITROYD GERMANY PATENTANWALTSGESELLSCHAFT M, DE Ref country code: DE Ref legal event code: R082 Ref document number: 602012005237 Country of ref document: DE Representative=s name: MURGITROYD & COMPANY, DE Ref country code: DE Ref legal event code: R082 Ref document number: 602012005237 Country of ref document: DE Representative=s name: FLEISCHER, ENGELS & PARTNER MBB, PATENTANWAELT, DE Ref country code: DE Ref legal event code: R081 Ref document number: 602012005237 Country of ref document: DE Owner name: NUTRITION & BIOSCIENCES USA 1, LLC, ROCHESTER, US Free format text: FORMER OWNER: DOW GLOBAL TECHNOLOGIES LLC, MIDLAND, MICH., US |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20210318 AND 20210324 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20210325 AND 20210331 |
|
PUAH | Patent maintained in amended form |
Free format text: ORIGINAL CODE: 0009272 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT MAINTAINED AS AMENDED |
|
27A | Patent maintained in amended form |
Effective date: 20220608 |
|
AK | Designated contracting states |
Kind code of ref document: B2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R102 Ref document number: 602012005237 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602012005237 Country of ref document: DE Representative=s name: MURGITROYD GERMANY PATENTANWALTSGESELLSCHAFT M, DE Ref country code: DE Ref legal event code: R082 Ref document number: 602012005237 Country of ref document: DE Representative=s name: MURGITROYD & COMPANY, DE |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20240209 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240130 Year of fee payment: 13 Ref country code: GB Payment date: 20240208 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240213 Year of fee payment: 13 |